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ABSTRACT
Despite advanced therapeutic strategies for post-myocardial infarction (MI) patients,
many ultimately develop congestive heart failure (CHF), rendering the disease a major cause of
death in the United States. MI is associated with an acute increase in sympathetic nervous system
activity, becoming persistent in CHF patients. Increased pro-inflammatory cytokines (PICs)
following MI are implicated in the pathogenesis of CHF. The increase in tumor necrosis factor
(TNF), a primary PIC, correlates closely with heart disease severity. Moreover, central PIC
production increases post-MI, and can affect the brain’s cardiovascular regulatory regions that
control sympathoexcitation. Therefore, understanding how PICs modulate sympathoexcitation is
important for development of new therapeutics. Recent studies underscore the importance of
central NADPH oxidases in the pathogenesis of hypertension. However, the role of central
NADPH oxidase-induced reactive oxygen species (ROS) production in the development of CHF
remains limited. In this dissertation, the hypothesis that central PICs induce ROS production and
modulate sympathoexcitatory neurons of the paraventricular nucleus (PVN) is explored through
an array of selective animal models combined with novel technologies for sympathoexcitation
and cardiovascular function assessment. The effect of the TNF blocker, pentoxyfylline, was
investigated on the expression of the catalytic subunits of NADPH oxidase (Noxs) in the PVN
neurons and on the sympathetic activity in CHF rats. Additionally, effects of TNF inhibition on
central nitric oxide were explored, as this ROS restrains sympathoexcitation. More specifically,
central TNF was inhibited to understand the interaction between superoxide and nitric oxide in
the PVN neurons during CHF. TNF knock-out mice were also used to study the effect of TNF on
volume overload associated with CHF. Finally, to understand the role of peripheral TNF on the
PVN’s sympathoexcitatory neurons, and to exclude the effects of neurohormones in CHF, human
recombinant TNF was injected 5-days systemically to achieve the levels observed following MI
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in conjunction with ROS and angiotensin II type-1 receptor blockers. These studies provide new
evidence that TNF induces oxidative stress in the PVN through an AT1R mediated mechanism in
CHF, and offers new insight into the sympathoexcitatory mechanisms in the brain possibly
involved in the pathogenesis of CHF.
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CHAPTER 1
BACKGROUND
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CYTOKINES AND CARDIOVASCULAR DISEASE
Cardiovascular disease has been the leading cause of mortality among Americans over
the last few decades. Current epidemiological studies indicate that there were approximately 1.2
million American adults who suffered from at least one type of cardiovascular disease in 2008
and that 1 of every 2.8 deaths in the United States is from a cardiovascular event (Rosamond et
al., 2008). Inflammation has become one of the main themes involved in the pathogenesis of
cardiovascular diseases, including myocardial infarction, ischemia-reperfusion injury,
myocarditis, atherosclerosis and congestive heart failure (Mehra et al., 2005). Following acute
myocardial infarction, systemic response is associated with increased expression of
inflammatory cytokines, such as tumor necrosis factor-α (TNF), interleukin-1β (IL-1β) and
interleukin-6 (IL-6), both in the blood and myocardium (Torre-Amione et al., 1995). According
to the ‘cytokine hypothesis of heart failure’, the progression of heart failure is, at least in part, a
result of the direct toxic effects exerted by elevated cytokines (Seta et al., 1996). TNF, IL-1β and
IL-6 are pro-inflammatory cytokines that damage myocytes and exert negative inotropic effects
on the heart (Shan et al., 1997). IL-10, on the contrary, is an anti-inflammatory cytokine that
protects cardiac function via inhibition of TNF and IL-6 production (Wang et al., 1995). The
progression of heart failure, thus, is dependent upon the balance between the production of TNF
and IL-10 following the initial insult.
Tumor Necrosis Factor in Congestive Heart Failure. TNF, a multifunctional proinflammatory cytokine originally identified as a factor associated with the necrosis of tumor
tissue triggers other cytokine and chemokine production, induces expression of cell adhesion
molecules, and causes cytotoxicity. This pleiotrophic cytokine exists either as a membrane bound
pre-protein or, after being cleaved from its pre-protein by metallopreoteinases, as a mature
soluble TNF (Gearing et al., 1994). Both, membrane and soluble TNFs can form homotrimers
2

which are essential for activation of TNF receptors. TNF actions are initiated by binding to a low
affinity 55 kD receptor, TNFR1 or a high affinity 75 kD receptor, TNFR2. These receptors,
when stimulated by certain factors, are shed into the circulation and become soluble receptors.
The soluble form of receptors act as a buffer by binding to the circulating TNF and preventing
their toxic effects, but can release the TNF into circulation when exposed to stress inducing
stimuli, exasperating the effects of TNF (Feldman et al., 2000).
Both types of TNF receptors are identified in non-failing (Torre-Amione et al., 1995) and
failing human myocardium (Torre-Amione et al., 1996). However, normal myocardium does not
produce TNF, whereas stressed myocardium expresses significant amounts of TNF. Feldman’s
laboratory developed a line of mice that harbored a transgene effecting cardiac-specific
overexpression of TNF alpha. This mouse line was generated using the cardiac-specific alpha
myosin heavy chain (alpha-MHC) promoter producing a phenotype with dilated cardiomyopathy
accompanied by increased inflammation (Kubota et al., 1997). These findings were further
confirmed by Bryant and colleagues (Bryant et al., 1998), who over-expressed TNF in hearts of
transgenic mice, and determined that they expressed a phenotype characterized by systolic
dysfunction, cardiac inflammation, ventricular dilatation, congested tissue, and increased
mortality. Additionally, either a single bolus, or continuous infusion of TNF, can induce LV
dysfunction and remodeling in various animal models (Bozkurt et al., 1998; Bradham et al.,
2002; Kimura et al., 2006). These studies suggest that overproduction of TNF by cardiac
myocytes is sufficient to cause severe cardiac disease. When the stress-activated cytokines in the
myocardium exceed the limit which can be utilized by the local cellular receptors in an
autocrine/paracrine capacity, they become blood borne and enter the systemic circulation,
causing some of the additional adverse effects associated with cytokines. Levine et al., first
recognized in 1990 that circulating levels of TNF were elevated in patients with end-stage heart
3

failure (Levine et al., 1990). Subsequent studies further suggested that there was a direct
relationship between circulating TNF levels and functional heart failure classification (TorreAmione et al., 1996).
In heart failure, the expression of cytokines parallels the expression of classical
neurohormones (Ferrari et al., 1995). However, increased circulating cytokine levels were
observed prior to that of neurohormones (El-Menyar, 2008), suggesting them as potential
stimulators of the vicious cycle of congestive heart failure.
SYMPATHOEXCITATION AND HEART FAILURE
Unregulated neurohumoral excitation is the hallmark of congestive heart failure (Francis
et al., 2001; Zucker et al., 2004; Negrao and Middlekauff, 2008). This increase in
neurohormones is initially targeted to improve cardiac function, but persistent elevation results in
a generalized increase in sympathoexcitation, enhanced renal sodium and water reabsorption,
and decreased renal perfusion resulting in the activation of a number of peptides including those
of the renin-angiotensin system (RAS) (McKinley et al., 2001).
Autonomic Regulation of Sympathoexcitation in Heart Failure. Heart failure is unique
among conditions activating the immune system, in the sense that the central effects of the
circulating cytokines, acting to regulate the peripheral immune response, are superimposed on, or
at least coincidental with, the central effects of the RAS in acting to preserve volume and
pressure within a compromised cardiovascular system. Changes in venous volumes of less than
1% are signaled to the brain via the afferent venous volume receptors utilizing autonomic nerves
and contribute to the pressure and volume adjustments through the neuroendocrine system
(Gupta et al., 1966; Coote, 2005). Similarly, the nucleus tractus solitarius (NTS) of the medulla
oblongata is the integral site for the afferent vagal fibers and baroreceptor afferents. The volume
signal originating in the NTS travels to the hypothalamus to influence the magnocellular
4

peptidergic neurohypophyseal neurons of the paraventricular nucleus (PVN), which play a key
role in neuroendocrine control of fluid balance. In addition, the parvocellular neurons of PVN
send axons to sympathetic outflow centers in the rostral ventrolateral medulla (RVLM) and
intermediolateral cell column of the spinal cord, which maintains tonic sympathetic vasomotor
outflow.
Besides the systemic baroreceptors and chemoreceptors, the subfornical organ (SFO),
organum vasculosum lamina terminalis (OVLT), and area postrema (AP) are unique blood-brainbarrier-deficient regions, also known as circumventricular organs (CVOs), that are primary
sensors for blood-borne neuropeptides such as cytokines (Ericsson et al., 1995) and AngII (Potts
et al., 1999). Neural pathways originating from these sensory CVOs project into an extensive
neural network that is responsible for mobilizing the various systems responsible for maintaining
homeostasis, i.e. vasopressin release, autonomic responses, and ingestive behaviors (Wallace
Lind et al., 1984; Ferguson and Kasting, 1988). SFO sends direct projections to the
magnocellular neurosecretory cells of the SON and PVN and the parvocellular neurons of the
PVN (Miselis, 1981; Jhamandas et al., 1989). The magnocellular neurons of the SON and PVN
are sites for vasopressin and oxytocin synthesis and fibers from these two regions project to the
neurohypophysis where the hormones are released into the circulation to exert their peripheral
effects. The parvocellular neurons of the PVN send axons to the RVLM and IML regions of the
brain that regulate sympathetic outflow and baroreflexes (Dampney, 1994). Thus, this evidence,
demonstrating that cytokine and AngII-sensing nerve cell bodies project to magnocellular and
parvocellular hypothalamic nuclei, neurohypophyseal tracts, the ventrolateral medulla and
brainstem, led to the hypothesis that these neuropeptides in the central nervous system function
as modulators in cardiovascular regulatory networks.
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Central Pro-inflammatory Cytokines and RAS in Sympathoexcitation. Intravenous LPS,
TNF (Ohashi and Saigusa, 1997) and IL-1 (Saindon et al., 2001) have been shown to increase
sympathetic discharge. It is interesting to note that in normal animals, acute and chronic
injection of TNF increases renal sympathetic activity (RSNA) (Saigusa, 1990) and production of
AngII (Bataillard et al., 1992). It has been well established that circulating levels of cytokines
and neuropeptides, like AngII, are elevated in CHF. Already, we have reported that treatment of
HF rats with a TNF binding agent, or transcription inhibitory factors, attenuates neuro-humoral
excitation (Kang et al., 2008). These findings suggest a direct role for TNF in inducing
sympathoexcitation.
REACTIVE OXYGEN SPECIES AND HEART FAILURE
Reactive oxygen species (ROS) encompass a variety of diverse chemical species that are
considered as toxic by-products of cellular metabolic processes designed to reduce molecular
oxygen. ROS includes free radicals such as superoxide (O2•-), nitric oxide (NO•), or hydroxyl
radicals (HO•), as well as non free radicals such as H2O2, while the antioxidant systems includes
host defense enzymes (catalase, superoxide dismutase, glutathione peroxidase, etc.), vitamins
and other molecules (thioredoxin/thioredoxin reductase, glutathione/glutathione reductase, etc.)
(Lambeth, 2004). Nitric oxide (NO•), and its oxidized form, peroxynitrite (ONOO-), result from
a reaction between NO• with either O2•- or HO•, also represent ROS, but are often referred to as
reactive nitrogen species (RNS). At physiological concentrations, ROS have certain desirable
effects. They act as second messengers in various cellular functions. Local ROS production also
regulates enzymatic function, and plays a role in signal transduction (redox signaling). ROS were
also shown to be essential for cell proliferation and growth, stimulate DNA synthesis and induce
expression of protooncogenes such as c-fos, c-jun, and c-myc (Rao and Berk, 1992). But at high
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concentrations, ROS are capable of inducing oxidation and damage of macromolecules, proteins,
lipids, mitochondria and DNA, thereby leading to cell damage, apoptosis and necrosis.
Multiple lines of evidence suggest that ROS contribute significantly to the hypertrophy
and remodeling mechanisms in heart failure. ROS production is triggered in cases of repetitive
ischemia-reperfusion, increased pro-inflammatory cytokine levels, auto-oxidation of
catecholamines, and synthesis of catecholamines. Some important sources of ROS in left
ventricular hypertrophy (LVH) and congestive heart failure (CHF) are xanthine oxidase,
mitochondria, uncoupled nitric oxide synthases, NADPH oxidases and infiltrating inflammatory
cells. Evidence from the past decade shows that ROS derived from NADPH oxidase are involved
in redox signaling. Furthermore, increased NADPH oxidase(s) activity and expression were
identified in the myocardium of patients with both ischemic and non-ischemic heart failure
(Heymes et al., 2003; Maack et al., 2003; Nediani et al., 2007).
NADPH Oxidase Enzyme Complex as a Source of Superoxide. The classical phagocytic
NADPH oxidases, first identified in neutrophils, are involved in oxidative burst aiding in host
defense against microbes and in phagocytosis (Roos et al., 2003; Lambeth, 2004). These multisubunit enzymes consist of the membrane-bound flavocytochrome comprising a catalytic Nox
subunit and p22phox subunit, and 4 cytosolic regulatory subunits, p40phox, p47phox, p67phox, and the
small GTP-binding protein Rac. Electron transfer occurs from NADPH to molecular oxygen at
the catalytic site, resulting in the formation of superoxide. In the last decade, several isoforms of
functional NADPH oxidases were identified in various non-phagocytic cell types. Some of the
agonists/stimuli related to myocardial remodeling and heart failure that activate NADPH
oxidases are G-protein coupled receptor agonists including AngII and endothelin (Duerrschmidt
et al., 2000; Li and Shah, 2003), cytokines such as TNF (Frey et al., 2002; Li et al., 2002),
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growth factors, mechanical forces (Hwang et al., 2003) and hypoxia-reoxygenation (Kim et al.,
1998).
There are 5 Nox isoforms (Nox1–5), expressed in a tissue-specific manner. Each NADPH
oxidase isoform contains a catalytic Nox subunit (which facilitates electron transfer) and a
smaller p22phox subunit that associate to form a heterodimeric cytochrome. This association is
important for the stabilization of the enzyme complex, as well as to bind to the other subunits.
Some of the isoforms, such as Nox1 and Nox2, require additional protein subunits for activation
of the enzyme. Nox2 (known previously as gp91phox) is the isoform that comprises the core of the
classical phagocytic NADPH oxidase, but is now known to also be expressed in several other
cell types, such as cardiomyocytes (Bendall et al., 2002) and fibroblasts (Pagano et al., 1997).
Nox2 requires four other subunits for activation, including p47phox, p67phox, p40phox and the small
GTP-Rac. The activation of Nox1-containing oxidase is highly similar to that of Nox2, although
it is believed to involve homologues of p67phox and p47phox, known as NOXA1 and NOXO1,
respectively (Lambeth, 2004). On the contrary, the activation of Nox4 is distinct in that it does
not appear to require any of the conventional regulatory subunits (Ambasta et al., 2004; Martyn
et al., 2006). The mechanisms responsible for regulating Nox4 activity remain poorly
understood.
Li et al. (2002) reported that the subunit expression of NADPH oxidase and its activity is
increased in parallel with the activation of MAPKs. An increase in the expression of the subunits
Nox2 and p22phox was also observed after MI both in human (Krijnen et al., 2003) and animal
myocardium (Fukui et al., 2001). Nox2 plays an important role in contractile dysfunction, while
Nox4 is important in the development of LVH. A small GTP-binding Rac1, which is important
in the activation of NADPH oxidase, is involved in ANG II-induced cardiomyocyte hypertrophy
(Pracyk et al., 1998). Potential redox sensitive downstream targets include Ras, c-Src, MAPKs
8

(ERK1/2, p38MAPK, JNK), p90SRK, PI3K, Akt, AP-1, NFkB, hypoxia-inducible factor-1 (HIF1) and others (Cave et al., 2005).

Figure 1. Non-phagocytic NADPH Oxidase may contain Nox1 or Nox4 as homologues for the
catalytic subunit gp91phox/Nox2. Superoxide is produced intracellularly and may require the
presence of all cytosolic subunits.
Inflammation and NADPH Oxidases in the Central Nervous System. The
phagocytic/microglial NADPH oxidase is known to be largely involved in the oxidative damage
induced in Alzheimer’s disease. The oxidative damage in CNS is generally manifested by lipid
peroxidation and formation of protein oxidation products that are toxic to neurons. In
Alzheimer’s disease, when stimulated by inflammatory stimuli or fibrillar β-amyloid, the
NADPH oxidase in the microglia is activated, initiating a series of intracellular signaling
cascades responsible for release of ROS and RNS (Akiyama et al., 2000). In addition, the
astrocytes, cells that can release pro-inflammatory cytokines TNF and IL-β, and nitric oxide
(NO), also produce NADPH oxidase-dependent ROS. Abramov and colleagues, using
astrocyte/neuronal co-cultures examined that β-amyloid particles induce oxidative stress in
9

astrocytes resulting in neuronal cell death. Furthermore, recent studies have implicated neuronal
NADPH oxidase in causing neurotoxicity and neuronal cell death. For example, presence of
Nox2 in cultures of cortical and sympathetic neurons has been reported and Nox4 expression is
also found upregulated in the brain cortex following cerebral ischemia (Vallet et al., 2005).
Recent reports also indicate the importance of gp91phox/Nox2 and Nox4 in the regulation of
cerebral vascular tone (Chrissobolis and Faraci, 2008).
Accumulating evidence show that schizophrenic patients suffer from diminished
antioxidant defenses in the brain. Recently, the role of IL-6 cytokine has been identified in
ketamine induced NADPH oxidase activation in the brain, leading to dysfunction of a subset of a
GABAergic phenotype of fast-spiking parvalbumin-interneurons, thus causing the pro-psychotic
effects of ketamine (Behrens et al., 2008). Although the role of cytokines in the pathophysiology
of many inflammatory brain diseases has been well studied, current knowledge on cytokine
activated forms of NADPH oxidases expressed in the cardiovascular regulatory centers in the
brain in CHF remain limited.
AngII Induced NADPH Oxidase Activation in the Central Nervous System. Recent studies
from Griendling’s laboratory identified angiotensinII as a potential activator of NADPH oxidase
in vascular smooth muscle cells (Lyle and Griendling, 2006; Lee and Griendling, 2008).
Subsequently, they, along with others, showed that SOD mimetics dramatically lowered blood
pressure in AngII, but not norepinephrine-induced, hypertension (Laursen et al., 1997;
Schnackenberg et al., 1998). Studies from Davisson’s lab showed that intracerebroventricular
injection of AngII modulated blood pressure and drinking behavior are mainly mediated through
increased O2•− produced in the SFO (Zimmerman et al., 2002). Notably, intracerebroventricular
injection of adenoviral vectors that expressed Mn-SOD or Cu/Zn-SOD blocked these effects of
AngII.
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The AngII type-1 receptors (AT-1Rs), the major receptor subtype, is predominantly
expressed in central regions that secrete vasopressin and control sympathoexcitation, including
the VLM, NTS and PVN (Bunnemann et al., 1992; Johren et al., 1995). In addition, AT-2
receptors expressed in forebrain, brainstem and hypothalamus were also shown to be related to
blood pressure regulation (Johren et al., 1997). Intracerebroventricular injection of AngII was
shown to increase systemic blood pressure (Davisson et al., 1998; Davisson et al., 2000).
Additionally, AngII-induced ROS in the RVLM are shown to modulate sympathetic nerve
activity and cardiovascular function in CHF (Mayorov et al., 2004; Gao et al., 2005). AngII also
increased the expression of gp91phox/Nox2 and p47phox in the RVLM, suggesting that AngII actions
are mediated by NADPH oxidase induced ROS. Blockade of AT-1Rs in the PVN (Han et al.,
2007) and RVLM (Mayorov et al., 2004) attenuated the generation of ROS, contributing to
decreased sympathetic activity in CHF.
Furthermore, Chan et al. showed that AngII-induced superoxide produced via NADPH
oxidases increased the phosphorylation of p38 MAPK and/or ERK1/2 in the RVLM, but not
JNK. These increases in the RVLM were attenuated by application of a flavin oxidase inhibitor,
DPI, antisense oligonucleotides that target p22phox and p47phox mRNA, or tempol. They also
observed that DPI, tempol and a p38MAPK inhibitor attenuated the frequency of glutamatesensitive excitatory postsynaptic currents and the blood pressure increase induced by AngII
(Chan et al., 2005).
Additionally, several studies report a cross-talk between pro-inflammatory cytokines and
the RAS in both humans and animals. These studies show that treatment with angiotensin II
(AngII) resulted in elevation of TNF-α in isolated heart preparations (Frolkis et al., 2001), while
pre-treatment with losartan, an AT-1R blocker, attenuated the TNF-α biosynthesis induced by
AngII (Gurlek et al., 2001), suggesting that AT-1R expression is closely related to that of TNF-α
11

in the heart (Tsutamoto et al., 2000; Gurlek et al., 2001). These studies explain an apparent
interaction between cytokines and AngII in the periphery. However, the cytokine-AngII
interaction in the PVN of CHF animals is currently unexplored.
Nitric Oxide in Sympathetic Regulation of Heart Failure. Functional studies suggest that
apart from AngII, nitric oxide (NO) within the PVN and SON, as an atypical neurotransmitter,
can elicit multiple actions and play a crucial role in the regulation of sympathetic tone. NO
synthase (NOS) positive neurons are detected primarily in the PVN and SON regions.
Electrophysiological studies indicated that administration of a NO donor into the PVN
siginificantly reduced BP, HR, and RSNA (Horn et al., 1994; Zhang et al., 1997), while the
converse has resulted with administration of a NO blocker (Zhang et al., 1997), suggesting the
role of NOS positive neurons in the PVN. The message and the number of nNOS positive
neurons were shown to be substantially decreased in CHF (Patel et al., 1996; Zhang and Patel,
1998). On the contrary, overexpression of nNOS in the rostral ventrolateral medulla (RVLM)
normalized the reduced baroreflexes in CHF, suggesting the role of central NO in baroreflex
function (Wang et al., 2003).
More recent evidence shows that ROS decrease NO bioavailability, which is an important
factor in the pathology of many disease processes (Cai and Harrison, 2000). All cell types in the
brain, in response to inflammation, produce significant amounts of NO via inducible nitric oxide
synthase (iNOS) that acts synergistically with superoxide producing NADPH oxidase to kill
neurons by formation of OONO-. Peroxynitrite can directly oxidize proteins, lipids and DNA
and promote tyrosine nitration and nitrosylation of cysteine, resulting in enzyme and protein
dysfunction, eventually leading to neuronal cell death. Formation of OONO- has been attributed
in the pathogenesis of many CNS disorders. Moreover, non-cytotoxic concentrations of the
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excitatory amino acid, glutamate has been shown to increase production of O2•- and OONO- via
induction of inflammatory mediators (Scott et al., 2007).
STATEMENT OF THE PROBLEM AND SPECIFIC AIMS
Increased circulating levels of cytokines lead to increased production of ROS and AngII,
resulting in the progression of heart failure. It has been demonstrated that the PVN and RVLM
of the CNS play a key role in the regulation of sympathetic outflow and progression of
cardiovascular disease. Peripheral cytokines can act on specialized brain regions known as
circumventricular organs, which lack a blood-brain-barrier, altering central cardiovascular
outputs including sympathoexcitation, release of vasopressin, and dampening of baroreflexes.
In addition, cytokines produced in the PVN and RVLM of the brain may also alter
cardiovascular and body fluid homeostasis. In order to better understand the central actions of
cytokines in the development of sympathoexcitation and to identify novel, central therapeutic
targets of the disease, it is essential to investigate the signaling mechanism(s) of cytokines in the
central nervous system.
Recent work in hypertension has identified ROS produced by NADPH oxidase as key
signaling intermediates of AngII in the PVN and SON. Furthermore, decreased NO in these key
central cardiovascular regulatory centers results in sympathoexcitation. However, the role of
NADPH oxidase-derived ROS in cytokine signaling in neurons within the CNS, and the role of
centrally produced ROS in cytokine-induced changes in sympathetic outflow and body fluid
balance, has not been studied. Therefore, we tested the hypothesis that the O2•--NO interaction
via the activation of AT1Rs are key signaling molecules and mediate the cardiovascular actions
of cytokines acting in the central nervous system. Furthermore, we hypothesize that
dysregulation of cytokine/AngII/ROS signaling in the brain is involved in the pathogenesis of
congestive heart failure.
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In order to explore our hypothesis, we performed a series of in vivo experiments
integrated with cardiovascular physiological, molecular and immunohistochemical techniques.
Aim 1: Determine the role of TNF in mediating oxidative stress in the PVN and inducing
sympathoexcitation in congestive heart failure.
Aim 2: Investigate the effects TNF on nitric oxide in the PVN, and its effect on
sympathoexcitation in heart failure.
Aim 3: Examine the effects of TNF upon the superoxide-nitric oxide interaction and
AT1R expression in the sympathoexcitatory neurons of the PVN, and upon volume overload in
congestive heart failure.
Aim 4: Determine the chronic systemic treatment effects of TNF in inducing oxidative
and nitrosative stress in the heart and the PVN, and understand the mechanism by which
increased TNF in the PVN contributes to increased oxidative stress and sympathoexcitation.
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CHAPTER 2
TNF-α BLOCKADE DECREASES OXIDATIVE STRESS IN THE
PARAVENTRICULAR NUCLEUS AND ATTENUATES SYMPATHOEXCITATION IN
HEART FAILURE RATS*

*Reprinted with permission of “American Journal of Physiology: Heart and Circulatory
Physiology”
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INTRODUCTION
Congestive heart failure is characterized by a generalized state of neurohumoral
excitation that contributes to progressive deterioration of cardiac function resulting in the
premature death of patients. In the past, most of the treatments were aimed at blocking this
exaggerated neurohumoral excitation by using β-adrenergic receptor antagonists, angiotensin
converting enzyme inhibitors, and angiotensin receptor blockers in heart failure (HF) patients.
These treatments have considerably reduced mortality and morbidity, however the clinical course
of CHF is still progressive, hence the need for innovative approaches to therapy.
In addition to neurohormones, the activation of proinflammatory cytokines such as TNFα is known to play a role in the pathogenesis of cardiovascular disease. These cytokines are
increased with the severity of heart disease and are of prognostic significance. Despite the
abundant evidence that TNF-α contributes significantly to cardiac dysfunction in heart failure in
animal models, the results of two large clinical trials using etanercept, a truncated, soluble TNF
receptor antagonist (RENAISSANCE) and infliximab (RECOVER), a TNF-α blocking antibody,
were largely negative (Mann et al., 2004). However, Pentoxyfylline (PTX), a phosphodiesterase
inhibitor, which also blocks cytokine expression, has been found to be promising in small
clinical trials (Sliwa et al., 2002). In addition to elevating intracellular cyclic AMP, PTX
increases the production of prostacyclins and vasodilatory eicosanoids (Myers et al., 1994;
Schermuly et al., 2001) and depresses the production of TNF-α (Strieter et al., 1988).
The concept of targeting brain production of neurohormones is relatively new and
understudied. Recent evidence from our lab suggests that cytokines are not only increased in the
circulation and LV tissues, but also in the hypothalamus of CHF rats (Francis et al., 2004). We
also showed that cardiac sympathetic afferents contribute to hypothalamic production of
cytokines and that the vagal efferents regulate the peripheral production of cytokines, thus
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suggesting a nervous system link in the activation of cytokines in CHF (Francis et al., 2004). In
the brain, the PVN of the hypothalamus is an important center regulating cardiovascular and
fluid homeostasis. Electrophysiological studies show that stimulation of PVN results in increased
sympathetic activity(Kannan et al., 1989). PVN neuronal activity is increased in HF rats.
Injection of TNF-α into the PVN or rostral ventrolateral medulla (RVLM) increased sympathetic
activity suggesting a direct role of TNF-α in sympathetic activity(Zhang et al., 2003).
Nevertheless, the mechanisms by which cytokines contribute to the sympathoexcitation in heart
failure are not known.
Oxidative stress plays an important role in the progression of CHF. Both in vitro and in
vivo studies have associated TNF-α as an important contributor to oxidative stress, either directly
or indirectly, by decreasing coronary or systemic perfusion resulting in cardiac dysfunction.
Furthermore, TNF-α modulates the activity and expression of NAD(P)H oxidases (Noxs), a
potential source of reactive oxygen species (ROS) in cardiovascular disease. NAD(P)H oxidase
is a multisubunit enzyme complex that consists of two membrane subunits, p22phox and Nox2,
and four cytoplasmic subunits, p40phox, p47phox, p67phox and Rac1. The catalytic subunit of
NAD(P)H oxidases is Nox2, and few isoforms of Nox2, such as Nox1 and Nox4, are found in
cardiomyocytes and neurons. The role of TNF-α in eliciting NAD(P)H oxidase subunit
expression in CHF is relatively unknown.
Taken together, it is evident that TNF-α contributes significantly to oxidative stress and
sympathoexcitation in the pathogenesis of CHF. To understand the mechanistic link between
CHF induced production of cytokines, and neurohumoral excitation, we hypothesized that
increased levels of TNF-α in CHF may modulates the expression of Nox2 or its isoforms in the
PVN and contributes to the exaggerated sympathetic activity. In this study we used PTX to block
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the production of cytokines both at the center and the periphery, as it is the only available drug
known to cross the blood-brain barrier (BBB).
METHODS
Animals. Adult male Sprague-Dawley rats weighing 350–375 g were used for this study. They
were housed in temperature (23 ± 2°C) and light-controlled (lights on between 7 AM and 7 PM)
animal quarters and were provided with water and rat chow ad libitum. The experimental
procedures were approved by the Louisiana State University Institutional Animal Care and Use
Committee.
Experiment Protocol. Rats underwent coronary artery ligation (CAL) to induce HF under
ketamine + xylazine anesthesia (90 and 10 mg/kg IP), or Sham operation (Sham), as described
previously (Francis et al., 2001). Induction of HF was confirmed by transthoracic
echocardiography 24 hours after recovery from surgery and the rats were assigned to different
treatment groups. Thereafter, HF or SHAM rats were chronically injected with PTX (30 mg/kg
daily IP; in 10% ethanol), or vehicle (10% ethanol alone) for 5 weeks. A second echocardiogram
was obtained at the end of the treatment protocol and the rats were sacrificed under isoflurane
anesthesia; plasma and other tissues were collected for further analysis.
Echocardiographic Assessment of LV Function. A first echocardiography was performed 24h
after coronary artery ligation followed by a second echo at the end of 5week study as described
previously (Francis et al., 2004). In brief, transthoracic echocardiography was performed under
ketamine anesthesia, using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin, California) fitted
with a PST 65A sector scanner (8 MHz probe) which generates two dimensional images at a
frame rate ranging from 300-500 frames per second. LV end diastolic volume (LVEDV) and
ejection fraction (EF) were computed using the area length method. The portion of the LV that
displays akinesis was electronically planimetered and expressed as a percent of the total LV
26

silhouette to estimate the size of the ischemic zone (% IZ). Only rats with large infarct (% IZ 
45%) were used for the study. LV fractional shortening (FS %) was calculated using the
following equation FS % = [(LVDD-LVESD)/LVEDD] x 100. Tei index was determined from
Doppler recordings of LV inflow and outflow as described previously (Dujardin et al., 1998).
From mitral inflow, isovolumetric relaxation time and isovolumetric contraction time were
measured. Ejection time was measured from LV outflow velocity curve recorded from long-axis
view. The Tei index was calculated using the equation, Tei index = (isovolumetric relaxation
time + isovolumetric contraction time)/ventricular ejection time.
Detection of ROS in the Heart and Brain. ROS were detected using Dihydroethidium (DHE)
staining. DHE is a fluorogenic probe, which in presence of ROS is converted to ethidium
bromide that intercalates with nuclear DNA, resulting in a punctuate appearance. The rats
received an intracardiac injection of DHE at a dose of 80 μg/kg body weight. Hearts and brains
were harvested, placed into freezing mold with Tissue-Tek® OCT (Sakura Finetek, Torrance,
CA), snap frozen with liquid nitrogen, sectioned on a cryostat and placed on slides. Cryosections
(12 μm) were immediately viewed and imaged under epifluorescence with a Zeiss Axiovert 200
microscope using an Ethidium Bromide (EtBr) compatible filter set (Chroma Filters #41006);
images were captured with an Olympus Q Capture 5 camera and Q Capture Pro software.
Extraction of PVN by Laser Capture Microscopy (LCM). LCM was conducted in a
dehumidified room (humidity ≤35%), and was kept to less than 30 min per slide to reduce the
loss in recovery of intact RNA. A 7.5 μm laser spot size was used to capture the PVN, at a power
range of 65–80 mW and pulse duration of 550–750 μs. This combination of parameters allowed
efficient retrieval of the entire PVN area and a consistent lifting efficiency of >80%. The number
of laser ‘shots’ used for each sample was kept constant at 1400. These parameters secured a
sufficient and near constant amount of input RNA for comparative real-time RT-PCR analyses
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and protein for western blotting. All experiments were performed no less than five times with
five different animals.
Measurement of Circulating TNF-α. At the end of the 5-week study, one group of rats was
sacrificed by decapitation with guillotine under deep anesthesia by isoflurane and approximately
4 mls of trunk blood was collected in heparinized tubes. Plasma samples obtained by
centrifugation of heparinized blood at 4ºC (Beckman-Coulter) at 2500 rpm for 15 min were used
for estimation of circulating TNF-α and catecholamines. Circulating levels of TNF-α were
quantified using commercially available rat TNF-α ELISA kit (Biosource, Camarillo, CA) as
described previously (Tei et al., 1995; Francis et al., 2003).
Estimation of Circulating Catecholamine Levels. Plasma norepinephrine (NE) and
epinephrine (EPI) were measured using high performance liquid chromatography (HPLC) as
described previously (Francis et al., 2001) with minor modifications in plasma sample
preparation. Plasma samples were prepared by adding activated alumina, Tris buffer, EDTA and
internal standard DHBA, along with 0.5 ml of rat plasma. The samples were centrifuged and
supernatant separated and rinsed twice in ultra pure water and filtered through a Millipore filter
(Ultrafree MC UFC30GV00, Millipore Corp). Samples were filtered and injected into an Eicom
HTEC-500 system fitted with an HPLC-ECD.
Renal Sympathetic Nerve Activity (RSNA). One set of rats were subjected to recording of
RSNA. The left kidney was exposed by left retroperitoneal flank incision. The renal sympathetic
nerves were identified under a dissecting microscope, isolated free of the surrounding connective
tissue, and placed on a pair of platinum recording electrodes. Once an optimal signal-to-noise
ratio was achieved, the electrode and the renal nerve were covered with a dentistry impression
material (Coltene President). The signal was amplified with a Grass P511 band-pass amplifier
with low-frequency cutoff set at 30 Hz and high-frequency cutoff at 3 kHz. The amplified and
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filtered signal was channeled to an audio amplifier-loudspeaker (Grass model AM 8 audio
monitor) for auditory evaluation, and to a rectifying voltage integrator for quantification (Grass
model 7P10). The integrated voltage signals were acquired by a commercially available data
aqusition system (Acknowledge for Windows; Biopack, Santa Barbara, CA). Minimum and
maximum RSNA was detected using a intravenous bolus administration of phenylephrine (20
g/kg) and sodium nitroprusside (SNP; 100g/kg), respectively. At the end of the experiment the
background noise, defined as the signal recorded postmortem, was subtracted from actual RSNA
recorded, and subsequently expressed as percent of maximum (in response to SNP).
RNA Isolation and Real-time RT PCR. Total RNA was extracted from the LV and
microdissected PVN using TRIzol reagent (Invitrogen), and reverse transcribed using oligo dT
and reverse transcriptase. Expression levels of Nox1, Nox2, Nox4, TNF-α, and IL-1β mRNA
were determined using specific rat primers shown in table 1. GAPDH was used as housekeeping
gene. Real-time RT–PCR (qRT–PCR) was performed in 384 well PCR plates using Bio-Rad
PCR Master Mix (The iTaq SYBRTM Green Supermix with ROX) and the ABI Prism 7900
sequence detection system (Applied Biosystems). The PCR cycling conditions were as follows:
50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C). A
dissociation step (15 s at 95°C, 15 s at 60°C and 15 s at 95°C) was added to check the melting
temperature of specific PCR product.
Table 2.1. Sequence of Primers Used in Real-time RT-PCR.
Primer

Sense

Antisense

Genebank ID

TNF-α

3′-GTCGTAGCAAACCACCAAGC-5′

5′-TGTGGGTGAGGAGCACATAG-3′

D00475

IL-1β

3′-CTGTGACTCGTGGGATGATG-5′

5′-AGACCTGACTTGGCAGAGGA-3′

NM_031512

Nox 1

3′-CCCTGGAACAAGAGATGGAC-5′

5′-AATTGGTCTCCCAAAGGAGGT-3′

NM_053683

Nox 2

3′-CGGAATCCTCTCCTTCCT-5′

5′-GCATTCACACACCACTCCAC-3′

AF298656

Nox 4

3′-TTCTACATGCTGCTGCTGCT-5′

5′-AAAACCCTCCAGGCAAAGAT-3′

AY027527
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Western Blot Analysis of Nox Subunits. Protein was extracted from LV samples and laser
captured PVN samples in ice-cold buffer (10 mM Tris·HCl pH 7.4, 1 mM EDTA, 1% NP-40,
0.1% sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail (Roche). The
protein content in the supernatant was determined using a detergent compatible protein assay
(Bio-Rad). Protein samples (25µg) were resolved in a 10% SDS-polyacrylamide gel along with a
molecular weight marker and then transferred to polyvinylidene difluoride (PVDF) membrane.
The membranes were blocked at RT for 1h in 1% casein in PBS-T. Blots were then incubated
overnight at 4°C with the following primary antibodies: Nox1 (1:1000 dilution), and Nox2
(1:1000 dilution) (Santa Cruz Biotechnology). GAPDH (1:1000 dilution) was used as internal
control. Bound primary antibodies were detected with a horseradish peroxidase–labeled
secondary antibody (1:20,000; 1 hour) and enhanced chemiluminescence (AmerSham). The band
intensities were quantified using Kodak ID 3.6 imaging systems and normalized with GAPDH
levels.
Localization of TNF-α and Nox Subunits by Immunohistochemistry. Brain and heart tissue
were fixed in 4% paraformaldehyde and cut into 8μm thick-sections, then pretreated with 0.3%
hydrogen peroxide and 0.1% sodium azide in PBS for 10 min to inhibit endogenous peroxidase
activity. These sections were washed twice in PBS and incubated in blocking medium (1% BSA
and 10% normal goat serum in PBS) for 10 min. The sections were then treated with respective
primary antibodies Nox1 (1:100 dilution), Nox2 (1:100 dilution), Nox4 (1:100 dilution) and
TNF-α (1:100 dilution) (Santa Cruz Biotechnology) and incubated overnight at 4C. The sections
were again washed twice in PBS and incubated with secondary antibody, a peroxidase conjugated
IgG antibody for 30 min. Bound antibodies were detected with streptavidin-peroxidase complex
using 0.2 mg/ml 3,3'-diaminobenzidine tetrahydrochloride in PBS containing 0.003% hydrogen
peroxide. Negative control sections were incubated with secondary antibody alone.
30

Statistical Analysis of Data. All results are expressed as mean ± SEM. For statistical
analysis of the data, one-way ANOVA followed by Bonferroni's post hoc test, was performed
using GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California,
USA, to determine differences among groups. A p value of less than 0.05 was considered
statistically significant.
RESULTS
Effect of PTX Treatment on Survival of CHF Rats. A total of 101 rats were subjected to CAL
or Sham surgery and subsequently assigned to three sets of animals, one set for
immunohistochemistry, the second for mRNA, and the third for western blot analysis. The
average survival within 24h of surgery was 80% in the rats undergoing CAL and 100% in the
Sham group. Over the five week study, 2 of the CHF rats and 2 of the CHF+PTX rats died prior
to the designated time point, while none of the Sham animals died during the investigation.
Thus, over the course of the five weeks, PTX treatment had no apparent influence on the survival
(Table 2.1).
Effect of PTX on ROS Production in HF. ROS production in the heart and brain was assessed
by DHE fluorescence (Fig. 2.1). As indicated by the punctate staining of the nuclei, CHFinduced an increase in ROS production in the heart and brain tissues. In contrast, PTX inhibited
CHF-induced ROS production.
Effect of PTX on LV Function. Table 2.1 shows LV function in rats as measured by
echocardiography. Compared to Sham animals, CHF rats had reduced LVEF and increased
LVEDV and increased volume/mass ratio. There was no significant difference in the HR
between the two CHF groups. The average %IZ in both the CHF groups was >56% with a range
of 50-58% before and after the treatments. At the end of the five weeks, Tei index was increased
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by 59.38% and LVEF further declined by 21.21 % in the CHF group. In contrast, treatment with
PTX in the CHF group prevented further decline in LVEF and decreased Tei index.

Fig.2.1. Detection of Reactive Oxygen Species (ROS) by dihydroethidium (DHE) staining.
Under identical imaging conditions, production of superoxide is elevated significantly in the
heart (top) and brain (bottom) compared with Sham and pentoxifylline (PTX)-treated rats.
Effect of PTX on Cytokine Production in HF. To determine the effect of PTX treatment on
CHF induced production of TNF-α in the heart and PVN, we determined mRNA transcript levels
by real-time RT-PCR in the LV tissue, and in the PVN isolated using laser capture micro
dissection. Circulating levels of TNF-α were also measured by ELISA to estimate the anticytokine effects of PTX. As shown in figure 2.2A, the elevated levels of circulating TNF-α
found in CHF rats were restored to near normal levels with PTX-treatment. The LV of CHF rats
showed increased levels of TNF-α (~3.7 fold increase) when compared with those of PTXtreated rats (~1.7 fold increase), although the levels did not exactly reach the levels of Sham rats
(Figs. 2.2B and 2.2C).
To further ascertain the anti-cytokine effects of PTX in CHF rats, the protein levels of
TNF-α were assessed in the LV and PVN by immunohistochemistry. Immunohistochemistry
revealed that elevated levels of TNF-α in CHF were significantly attenuated by treatment with
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PTX (Fig. 2.2D). These results show that the TNF-α expression is significantly inhibited by
PTX both in the LV and the PVN of CHF rats.
Table 2.2. Echocardiographic Findings
Sham +
CHF + PTX 5
MI 24 h
CHF 5 wks
PTX
wks
n
18
18
48
23
23
415 ± 12.0
410 ± 5.00
409 ± 12.0
418 ± 6.00
411 ± 10.0
HR
IVSD (mm)
1.52 ± 0.05 1.55 ± 0.04 1.22 ± 0.09
1.14 ± 0.08*
1.53 ± 0.10#
IVSS (mm)
2.80 ± 0.09 2.72 ± 0.08 1.76 ± 0.12*
1.67 ± 0.13*
2.00 ± 0.16*
LVDD (mm)
6.41 ± 0.18 6.33 ± 0.14 7.75 ± 0.40
10.91 ± 0.72*
8.99 ± 0.17*,#
LVDS (mm)
3.03 ± 0.18 3.01 ± 0.06 5.92 ± 0.45*
8.12 ± 0.63*
7.80 ± 0.86*
PWD (mm)
1.67 ± 0.05 1.74 ± 0.08 1.17 ± 0.04*
1.26 ± 0.12*
1.45 ± 0.06
PWS (mm)
2.66 ± 0.10 2.70 ± 0.06 1.87 ± 0.12*
1.85 ± 0.15*
2.17 ± 0.07*
%EF
83.7 ± 0.90 84.6 ± 1.20 34.0 ± 0.20*
26.0 ± 1.20*
33.2 ± 2.40*,#
%FS
52.94 ± 1.96 51.79 ± 1.30 24.45 ± 2.34* 15.42 ± 1.26*
23.42 ± 2.41*
%IZ
0
0
54.9 ± 1.80
58.9 ± 2.60
55.8 ± 3.10
Tei
0.46 ± 0.02 0.44 ± 0.02 0.34 ± 0.03
0.51 ± 0.04
0.32 ± 0.03*,#
LVEDV (µl)
548 ± 56
520.3 ± 48.5 865 ± 40.2*
1015 ± 93.6*
868 ± 103*,#
Values are means ± SE; IVSD, Interventricular septal thickness at end-diastole; IVSS,
Interventricular septal thickness at end-systole; LVDD, Left ventricular internal diameter at enddiastole; LVDS, Left ventricular internal diameter at end-systole; PWD, Posterior wall thickness
at end-diastole; PWS, Posterior wall thickness at end-systole; %FS, percent fractional shortening
*P < 0.05, compared with Sham group
#P < 0.05, compared with CHF 5 wks group
Sham

Modulation of Expression of Nox1, Nox2 and Nox4 in HF. The mRNA expression of the
NAD(P)H oxidase subunits Nox2 and its isoforms (Nox1 and Nox4), were assessed by real-time
RT-PCR. CHF induced a ~6, 10 and 4 fold increase in Nox1, Nox2 and Nox4 in the LV (Figs.
2.3A, B and C), respectively. A similar increase was also seen in the PVN of CHF rats (~28, 15
and 6 fold increase, respectively) for Nox1, Nox2 and Nox4 compared to the Sham group (Figs.
2.3D, E and F). PTX treatment in the CHF group significantly reduced the expression of these
subunits in both the LV and PVN.
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Fig.2.2. Tumor Necrosis Factor (TNF)-α Levels. A: PTX inhibited congestive heart failure
(CHF)-induced production of circulating TNF-α (*P<0.05). B and C: CHFinduced mRNA
expression of TNF- α inhibited by PTX in the left ventricle (LV; B) and the paraventricular
nucleus (PVN; C). D: Immunohistochemistry photomicrographs of TNF-α in the LV and PVN.

Protein expression for Nox1, Nox2 and Nox4 was measured in the LV and PVN by
Western blot analyses. Unfortunately, we did not get a good signal on the Western blot with the
commercially available Nox4 antibody. As shown in figures 2.4A and 2.5A, CHF rats treated
with PTX exhibited a decrease in the protein expression of Nox1and Nox2 in the LV and PVN
(Figs. 2.4B and 2.5B).
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Immunohistochemistry also revealed an increased expression of Nox1, Nox2 and Nox4 in
the LV of CHF rats as compared to Sham and those treated with PTX (Figs. 2.4C, 2.5C and 2.6,
respectively). In the PVN, Nox1 was predominantly detected in the magnocellular neurons of
CHF rats (Fig. 2.4C). Nox2 and Nox4 expression was increased both in the magnocellular and
parvocellular neurons of the PVN of CHF rats. Treatment with PTX reversed all these changes
in the PVN of CHF rats (Figs. 2.5C and 2.6).

Fig.2.3. Effect of PTX
Treatment on mRNA Levels of
NAD(P)H Oxidase Subunits
[Nox1 (A), Nox2 (B), and Nox4
(C)] in the LV and PVN [Nox1
(D), Nox2 (E), and Nox4 (F)]
of Experimental Rats. Levels
of Nox1, Nox2, and Nox4 were
elevated in the LV and PVN of
CHF rats compared with the
Sham and PTX-treated
rats. *P <0.05.

Effect of Blocking Cytokines on Sympathetic Activity. Plasma epinephrine and
norepinephrine levels were significantly increased (995.5±89 and 576±56 pg/ml, respectively;
p<0.05) in the CHF rats. Following inhibition of cytokines with PTX, these catecholamine levels
were decreased significantly (347±42 and 192.9±29 pg/ml, respectively; p<0.05). These levels

35

showed a significant difference when compared to those of Sham rats (225±30 and 193±40
pg/ml, respectively; p<0.05) (Fig. 2.7A).
Figure 2.7B shows a raw tracing from a vehicle treated CHF rat and PTX treated CHF
rat. Figure 2.7C shows RSNA as a percent of maximum response to the hypotension induced by
intravenous injection of SNP. RSNA response to hypotension was maximum in CHF rats treated
with vehicle when compared to that of PTX-treated CHF rats. There was no difference in the
RSNA activity in vehicle and PTX treated Sham rats in response to hypotension.

Fig.2.4. Effect of PTX Treatment on Protein Expression of Nox1 Subunit. Representative
Western blot and densitometric analysis of Nox1 in the LV (A) and PVN (B). ***P<0.001 vs.
Sham; ###P <0.001 vs. CHF. Immunohistochemical localization of Nox1 in the LV and PVN of
CHF rats (C).
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DISCUSSION
The major findings of this study are 1) The expression of the NAD(P)H oxidase subunits,
Nox1, Nox2 and Nox4 were elevated in the LV and the PVN of CHF rats, 2) administration of
PTX, a blocker of proinflammatory cytokine production, normalized the enhanced NAD(P)H
oxidase subunit and TNF-α expression, both in the PVN and the LV, and 3) PTX also decreased
the circulating catecholamine levels and RSNA, indicators of sympathetic activity, in CHF rats.
These findings suggest that the cytokines play a role in inducing oxidative stress in the PVN,
thereby contributing to the increased sympathetic activity in CHF rats.

Fig.2.5. Nox2 Protein Expression. Representative blot and densitometric analysis of LV (A) and
PVN (B). ***P <0.001 vs. Sham; ###P< 0.001 vs. CHF. C: photomicrographs showing
expression of Nox2 in the LV and PVN of CHF rats. PTX attenuated Nox2 subunit expression
both in the LV and PVN of CHF rats. The sections shown are representative of results from 3
different experiments. Magnification is X100 in top and X400 in bottom.
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Pentoxifylline and LV Function. Cytokines are produced locally in the myocardium in
response to stimuli such as hemodynamic pressure overload and myocardial ischemia or
infarction (Torre-Amione et al., 1996; Baumgarten et al., 2002). Several clinical studies have
shown that PTX decreases proinflammatory cytokine production and improves LV function in
CHF patients (Sliwa et al., 1998; Skudicky et al., 2001; Sliwa et al., 2002; Bahrmann et al.,
2004; Sliwa et al., 2004). In this study also, we show that treatment with PTX in CHF rats
resulted in a significant improvement in LVEF and prevented an increase in the Tei index, an
indicator of systolic dysfunction. The Tei index is a combination of contraction and relaxation
time intervals constituting an overall index of LV function as assessed by Doppler
echocardiography. The Tei index has been shown to have prognostic importance in dilated
(Dujardin et al., 1998) and restrictive cardiomyopathies (Harjai et al., 2002), and also in acute
myocardial infarction (Moller et al., 2001). The Tei index has a narrow range in normal subjects
and seems to progressively increase with deterioration of LV function (Dujardin et al., 1998).
TNF-α exerts a negative inotropic effect on the contractility of the ischemic heart in hamsters,
dogs, and humans (Finkel et al., 1992) by interfering with calcium homeostasis, and thus
interfering with contraction-excitation coupling (Meldrum et al., 1998). PTX has been
demonstrated to exert protective effects on ischemic myocardium by reducing TNF-α production
(Zhang et al., 2005). In the present study, we saw a deterioration of LV function in the vehicle
treated CHF rats as indicated by decreased EF and increased Tei index. We also observed an
increase in LVDD and LVEDV, which indicate a decrease in LV contractile function. Treatment
with PTX improved LV contractile function in our study that could be due to a combined
reduction in cytokines and oxidative stress. This is supported by our observation that PTX
treatment decreased ROS production. It has been shown that the surviving myocytes in the
infarcted region are potential sources of cytokines, which may contribute to the progression of
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CHF (Irwin et al., 1999). This study further shows that PTX, by virtue of its anti-cytokine
activity, exerts its role in improving the systolic function in CHF, which is comparable to other
studies (Irwin et al., 1999; Skudicky et al., 2001; Gurantz et al., 2005).

Fig. 2.6. Photomicrographs Showing Expression of Nox4 in the LV (top) and PVN (bottom).
CHF increased the expression of Nox4 both in the LV and PVN of heart failure rats, whereas
PTX treatment attenuated this increased expression.
Cytokines and CNS in Congestive Heart Failure. When the stress-activated cytokines in the
myocardium exceed the limit to be utilized by the local cellular receptors in autocrine/paracrine
functions, they become blood-borne and enter the systemic circulation, causing some of the
adverse effects associated with cytokines. One critical function of blood-borne cytokines is to
stimulate self-production via a feed-forward mechanism. These blood borne cytokines are large
molecules and do not readily cross the BBB. However, they can enter the brain through a
saturable transport mechanism, or a passive transport mechanism via the circumventricular
organ, where the BBB is either weak or absent. Our previous studies showed that cardiac
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sympathetic afferents are a potential mechanism for the induction of hypothalamic cytokines in
CHF (Francis et al., 2004). Thus, the circulatory cytokines could induce inflammatory and
sympathoexcitaory mediators in the brain that have been shown to be antagonized by a
mineralocorticoid receptor blocker (Kang et al., 2006). The deleterious role of these stressactivated cytokines in the progression of heart disease could be due to the direct toxic effects
exerted by these cytokines on heart and circulation.

Fig. 2.7. Sympathetic Activity. A: circulating norepinephrine (NE) and epinephrine (Epi) levels
were significantly higher in CHF rats, whereas they were lower in those treated with PTX.
*P<0.05 compared with Sham. B: and C: raw tracing showing renal sympathetic nerve activity
(RSNA; B) and integrated RSNA (C) of CHF rats was higher in the vehicle-treated rats
compared with the PTXtreated rats. *P<0.05 vs. Sham; #P<0.05 vs. CHF.
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The PVN of the hypothalamus is one of the five major regions in the brain controlling
sympathetic outflow. It regulates sympathetic activity via its inputs from the nucleus tractus
solitarius (NTS) (Swanson and Sawchenko, 1983) and efferent projections to the RVLM and
intermediolateral column (IML) of the spinal cord (Pyner and Coote, 2000). The PVN is
composed of two kinds of neurons (Swanson and Sawchenko, 1983); the larger magnocellular
neurons projecting into the pituitary are responsible for humoral regulation of fluid balance,
whereas the smaller parvocellular neurons projecting to other sites in the CNS are involved in
mediating sympathetic activity (Patel, 2000).
It has also been shown that many putative mediators, like prostaglandins, facilitate the
transport of cytokines into the brain. These cytokines then stimulate the microglial cells in the
brain to produce even more cytokines. We have also shown that injection of prostaglandin-E2
increased sympathetic activity in HF rats (Zhang et al., 2003). In this study, we show
cardiosympathoexcitatory neurons of the PVN as yet another potential source of cytokines in
CHF. Moreover, the enhanced sympathetic activity in HF rats was decreased in the present study
concurrent with the administration of PTX as evidenced by attenuated circulating catecholamine
levels and RSNA. To observe the effects of central administration of PTX on RSNA, we
administered PTX (10µg/kg body wt.) chronically for 5 weeks using osmotic minipumps in a
group of rats (n=8) through intracerebroventricular (ICV) cannulation in CHF rats. No
significant difference in RSNA or other parameters was observed in the rats treated with PTX
either peripherally or centrally (data not shown). This shows that intraperitonial administration of
PTX exerts both central and peripheral effects. Though the antagonism of TNF-α was not
successful in larger clinical trials (possibly due to the fact that the Etanercept could bind to only
the circulating and not the membrane-bound tissue TNF-α) (Kelly and Smith, 1997), a small
clinical trial using PTX was successful in improving cardiac outcomes (Sliwa et al., 2002). Our
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results in the present study strongly suggest that using PTX decreases the tissue-bound TNF-α in
the PVN and LV.
Oxidative Stress and CHF. Apart from cytokines, ROS have also been implicated in the
pathogenesis of CHF. The NAD(P)H oxidases are one of the major sources of superoxide in the
heart. This multisubunit enzyme complex consists of two membrane subunits, p22phox and
Nox2, and four cytoplasmic subunits, p40phox, p47phox, p67phox and Rac1. Nox2 is the
catalytic subunit of NAD(P)H oxidase and it has other isoforms, namely Nox1 and Nox4, that
substitute Nox2 in cardiomyocytes and neurons.
NAD(P)H oxidases activated by Angiotensin-II, cytokines (eg.,TNF-α), endothelin-1 and
mechanical forces are shown to play an important role in cardiovascular dysfunction (Griendling
et al., 2000). Nox1 has been reported to be upregulated in TNF-α induced oxidative stress in
coronary arteries of hyperhomocysteinemic rats (Ungvari et al., 2003), while Nox4 is
upregulated in aortic smooth muscle cells treated with TNF-α (Moe et al., 2006). Nox2 is
demonstrated to be elevated in human CHF (Heymes et al., 2003) and this was also confirmed in
cardiomyocytes (Krijnen et al., 2003). In this study we show that Nox2 and its homologues,
Nox1 and Nox4, are upregulated in the LV and PVN of CHF rats. These results are also
positively correlated to the ROS production, as indicated by the DHE staining (Fig. 1). Inhibition
of TNF-α production by PTX has reversed these changes, suggesting a role for cytokines in
redox-sensitive signaling in CHF.
PVN and supraoptic nucleus are most strongly implicated in the re-dox mechanisms in
the post-MI neurodysregulation (Lindley et al., 2004). In our study, we too show that there is
increased ROS in the PVN, more specifically we show that ROS producing machinery is
increased in the PVN of CHF rats. Among the Nox’s shown, Nox1 is predominantly seen in the
magnocellular neurons of the PVN. Thus, it is possible that Nox1 could play a role in regulating
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neurohumoral mechanism contributing to CHF. Interestingly, Nox4 expression is increased both
in the magnocelluar and parvocellular neurons of the PVN. Nox2 is also increased in the
magnocellular and parvocellular neurons of PVN in CHF rats. These finding suggests that
expression of different Nox2 homologues in these cell bodies has a significant role in the
pathogenesis of CHF and raises the possibility that Nox2 and Nox4 overexpression in the
parvocellular neurons contribute significantly to neurohumoral excitation in CHF. Further
studies are needed to identify the role of these homologues in sympathoexcitation.
Recent studies showed that microinjection of a NAD(P)H oxidase inhibitor into the PVN
reduced the cardiac sympathetic afferent reflexes elevated by central ANG II or the epicardial
application of bradykinins (Zhang et al., 2006). Coupled with our findings that a cytokine
blocker, PTX, inhibits CHF-induced Nox expression in the PVN and LV, it suggests that oxidant
signaling via cytokines in the PVN may be involved in the reduction of catecholamine levels, and
RSNA in CHF. It is plausible that one might extrapolate that the effects of PTX observed in the
PVN could be due to its other varied effects. However, from the precise anti-cytokine and antioxidant effects of PTX observed in this study, it is convincing to conclude that decreased
cytokines resulted in the reduction of NAD(P)H oxidase subunits in the PVN, and thus,
sympathoexcitaion in CHF.
In conclusion, this study clearly demonstrates that the CHF induced an increase in TNF-α
in the PVN and in the LV contributes to the increased expression of NAD(P)H oxidase subunits,
Nox1, Nox2 and Nox4. Treatment with PTX, an inhibitor of cytokine production, attenuated the
mRNA and protein expression of these subunits and superoxide production, and also decreased
circulating levels of catecholamines in CHF rats. Our results suggest that cytokine-induced
oxidative stress in the central nervous system and in the periphery contribute to the
pathophysiology of CHF. Furthermore, these studies demonstrate that, for the first time, both
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cytokines and NAD(P)H oxidase in the PVN contribute to increased plasma catecholamine and
exaggerated neurohumoral excitation in CHF.
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CHAPTER 3
CYTOKINE BLOCKADE ATTENUATES SYMPATHOEXCITATION IN HEART
FAILURE: CROSS-TALK BETWEEN nNOS, AT-1R AND CYTOKINES IN THE
HYPOTHALAMIC PARAVENTRICULAR NUCLEUS*

*Reprinted with permission of “European Journal of Heart Failure”
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INTRODUCTION
Sympathetic hyperactivity is a striking feature of the syndrome of congestive heart failure
(CHF). Initially after myocardial injury, there is increased sympathetic activity even before the
onset of overt heart failure (Francis et al., 1990). When this sympathetic hyperactivity fails to
restore the functioning of the injured myocardium, it results in generalized sympathoexcitation
leading to increased vasoconstriction and ventricular remodelling.
Regulation of sympathetic activity is a complex process that involves the activation of
several neurohormones, including those of the renin angiotensin system (RAS). Blockade of the
AT-1R in the paraventricular nucleus (PVN) restores sympathetic activity in CHF (Zhang et al.,
2002). In a previous study we showed that elevated TNF-α and IL-1β in the PVN of rats with
acute myocardial infarction (MI) is mediated through cardiac sympathetic afferents (Francis et
al., 2004). Furthermore, we demonstrated that elevated cytokines in the PVN induce production
of reactive oxygen species (ROS) (Guggilam et al., 2007). ROS, produced in the neurons of the
brain, in turn, are cytotoxic, further perpetuating sympathoexcitatory effects (Dawson et al.,
1996). Studies from this and other labs have shown that pentoxifylline (PTX), a cytokine
synthesis blocker, reduced the central and peripheral production of cytokines and attenuated the
production of ROS, renal sympathetic nerve activity (RSNA), as well as plasma norepinephrine
levels, an indirect measure of sympathetic activity in CHF rats (Francis et al., 2004; Kang et al.,
2006; Guggilam et al., 2007). Additionally, several studies report a cross-talk between proinflammatory cytokines and the RAS in both humans and animals. These studies show that
treatment with angiotensin II (AngII) resulted in elevation of TNF-α in isolated heart
preparations (Frolkis et al., 2001), while pre-treatment with losartan, an AT-1R blocker,
attenuated the TNF-α biosynthesis induced by AngII (Gurlek et al., 2001), suggesting that AT1R expression is closely related to that of TNF-α in the heart (Tsutamoto et al., 2000; Gurlek et
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al., 2001). These studies explain an apparent interaction between cytokines and AngII in the
periphery. However, the cytokine-AngII interaction in the PVN of CHF animals is currently
unexplored.
Studies by Patel et al. showed that rats with CHF had a decreased message for neuronal
nitric oxide synthase (nNOS), and consequently, decreased nitric oxide (NO) in the PVN (Patel
et al., 1996; Zhang et al., 1998), indicating loss of regulation of sympathetic tone. Furthermore,
AngII-induced sympathetic hyperactivity disrupts the antagonistic mechanism of NO, while
increasing superoxide production. This emphasizes the cross-talk between ROS and RAS
mechanisms (Rajagopalan et al., 1996). However, it is unknown whether increased cytokines
interact with AT-1Rs within the PVN to modulate nNOS and contribute to sympathetic
hyperactivity in CHF rats.
In the current study, we examined the hypothesis that increased cytokines in the PVN upregulate AT-1R expression and deplete nNOS, contributing to exaggerated sympathetic activity
in CHF rats. We used PTX to block cytokine synthesis in CHF rats, as this phosphodiesterase
inhibitor has been documented to cross the blood-brain barrier (BBB) rapidly and efficiently
after systemic administration (Watkins et al., 2003), and inhibit production of TNF-α and IL-1β
(Yoshikawa et al., 1999).
METHODS
Studies were performed in male Sprague-Dawley rats weighing 250–300 g. To study the
effect of PTX on survival of CHF rats, the study was conducted in two phases. In phase I, rats
were pre-treated with PTX (30 mg/kg IP), or its vehicle (10% ethanol, IP), 24 h prior to
induction of CHF or Sham surgery, to study the effects on survival of pre-treatment with a
cytokine synthesis blocker. In Phase II, rats were subjected to CHF or Sham surgery and
subsequently treated with PTX (30 mg/kg IP, daily) or vehicle for a period of 5-weeks. No
51

significant difference was observed in the molecular and biochemical parameters analyzed
between PTX pre-treated and post-treated CHF groups. Therefore, the results from both of these
groups were combined and presented as CHF+PTX.
All procedures on animals in this study were approved by the Louisiana State University
Institutional Animal Care and Use Committee, and were in compliance with the Guide for the
Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
CHF Model. Heart failure was induced under ketamine+xylazine (90 and 10 mg/kg IP)
anaesthesia by coronary artery ligation. In brief, the trachea was intubated, and the rat was placed
on an Anesthesia Work Station (Hallowell EMC). A left thoracotomy was performed, the heart
was exteriorized and the left anterior descending coronary artery was ligated. Sham-operated rats
underwent thoracotomy and manipulation of the heart, except for the ligation of the coronary
artery. All rats received analgesics (Buprex, 1 ml/kg SC) following the surgery.
Assessment of LV Function
Echocardiography: Echocardiography was performed 24h after coronary artery ligation or
Sham surgery under ketamine (25 mg/kg IP) sedation. Infarct size was estimated by planimetric
measurement of the percentage of the LV that demonstrated systolic akinesis. Rats with infarct
size 50% were selected and thereafter treated with PTX or vehicle for 5-weeks. At the end of
the 5-week study, a second echocardiographic assessment was performed. Percent ischaemic
zone (%IZ), LV ejection fraction (EF), LV end-diastolic volume (LVEDV), and LV end-diastolic
volume-to-mass ratio, all indexes of severity of CHF, were determined from short- and long-axis
images of the left ventricle (LV). LV mass and volume were calculated using the area length
method. After completion of two-dimensional imaging, pulse-wave Doppler interrogation of
mitral inflow was performed to determine heart rate (HR). Cardiac output (CO) was calculated as
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the product of HR and stroke volume (SV). From mitral inflow, isovolumetric relaxation time
and isovolumetric contraction time were measured. The Tei index was calculated as described
previously (Guggilam et al., 2007).
Morphological Parameters: At the end of the study, the rats were sacrificed under deep
anaesthesia using a carbon dioxide chamber. Lung and left and right ventricular masses were
recorded, and the respective indices were obtained by dividing with body mass.
Survival. To calculate the survival in pre- and post-PTX treated groups, rats were monitored for
mortality following induction of MI.
Measurement of Circulating TNF-α. Circulating levels of TNF-α were quantified in the plasma
samples using a commercially available rat TNF-α ELISA kit (Biosource, Camarillo, CA) as
described previously (Tei et al., 1995; Francis et al., 2003).
Estimation of Circulating Catecholamine Levels. Plasma norepinephrine (NE) and
epinephrine (EPI) were measured in plasma samples using an Eicom HTEC-500 system fitted
with an HPLC-ECD using HPLC-EC as described previously (Guggilam et al., 2007).
Measurement of Renal Sympathetic Nerve Activity (RSNA). RSNA was measured in Sham
and CHF rats anesthetized with pentobarbital, as described previously (Guggilam et al., 2007).
Following equilibration, the maximum change (increase) in RSNA in response to an intravenous
bolus injection of sodium nitroprusside (SNP; 100 μg/kg) was measured in each animal. The raw
nerve activity, integrated nerve activity, mean arterial pressure (MAP), and HR were recorded on
a Biopac Acknowledge system. At the end of the experiment, the background noise, defined as
the signal recorded post-mortem, was measured and subtracted from the actual RSNA recorded,
and subsequently expressed as percent change in RSNA from baseline (in response to SNP).
Extraction of PVN by Laser Capture Microscopy (LCM). PVN was captured from frozen
brain sections by LCM, as described previously (Guggilam et al., 2007). All the parameters were
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set constant to attain a relatively equal amount of input RNA for comparative real-time RT-PCR
analyses and protein for western blotting.
RNA Isolation and Real-time RT PCR. Total RNA was extracted from the tissues as described
previously (Guggilam et al., 2007). Real-time RT–PCR (qRT–PCR) was performed in 384-well
PCR plates, using Bio-Rad PCR Master Mix (The iTaq SYBRTM Green Supermix with ROX) to
study the expression levels of TNF-α (X 66539), IL-1β (NM 031512), iNOS (NM 012611),
nNOS (NM 052799), AT-1R (NM 031009), and 18S (NR 003278) as the housekeeping gene
using the ABI Prism 7900 sequence detection system (Applied Biosystems).
NADPH Diaphorase Staining for nNOS. At the end of week 5, the rats for NADPH diaphorase
staining were anaesthetized and perfused transcardially with heparinized saline, followed by 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (PBS, pH 7.4). The brains were removed
and post-fixed at 4°C for 4 h in 4% paraformaldehyde solution and then placed in 20% sucrose at
4°C for 24h. Brains were blocked in the coronal plane, and 30-µm-thick sections were cut with a
cryostat. The sections were collected in 0.1 M PBS, containing 0.3% Triton X-100, 0.1 mg/ml
nitroblue tetrazolium and 1.0 mg/ml β-NADPH, and were then placed in an incubator at 37°C for
1 hr. After incubation, the sections were rinsed in PBS (pH 7.4) and mounted on glass slides.
NADPH-diaphorase positive neurons in the PVN of three adjacent sections at the same coronal
level were counted as described by Zheng et al (Zheng et al., 2005).
Immunohistochemistry. Immunohistochemistry was performed in formalin fixed sections of the
brain as described previously (Guggilam et al., 2007). The primary antibodies against nNOS and 3nitrotyrosine (3-NT) (Santa Cruz, CA) (1:100) were incubated overnight at 4C. The sections were
then washed twice in PBS, and incubated with a peroxidase conjugated 2° IgG antibody for 30
minutes. Bound antibodies were detected with a streptavidin-peroxidase complex using 3, 3'diaminobenzidine tetrahydrochloride in PBS containing 0.003% hydrogen peroxide.
54

Western Blot Analysis. Frozen LV, PVN and hypothalamus proteins were prepared and
fractionated in 7.5-10% polyacrylamide gel and transferred to an Immobilon membrane, as
described previously (Guggilam et al., 2007). Due to limitation in the quantity of PVN, we used
the hypothalamus for protein analysis of AT-1R. The membranes were blocked in 1% Casein in
Tris-buffered solution containing 0.1% (v/v) Tween-20 for 1 h and then incubated overnight with
antibodies (1:1000) against TNF-α, AT-1R, or nNOS (Santa Cruz, CA), followed by a
peroxidase-conjugated goat anti-mouse IgG antibody (1:10,000). The signal was detected using
an enhanced chemiluminescence immunoblotting detection system and the net intensity was
determined and expressed in relative arbitrary units by normalizing the protein intensity to that of
anti-GAPDH antibody.
Statistical Analysis of Data. All results are expressed as mean ± SEM. For statistical analysis of
the data, student’s t test, or one-way ANOVA followed by Bonferroni's post hoc test were used.
Survival among treated and untreated groups was analyzed using the Kaplan-Meier analysis of
survival followed by the Log-rank test (GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego, CA, USA). Values of p<0.05 were considered significant.
RESULTS
Effect of PTX Treatment on the Survival of CHF Rats. As shown in table 3.1, pre-treatment
with PTX significantly improved 24h survival after induction of CHF as compared to the posttreatment group. None of the Sham animals died during the entire study protocol.
Effect of Blocking Cytokines on Sympathetic Activity. Plasma norepinephrine (NE) and
epinephrine (EPI) levels were significantly increased in the CHF rats as compared to those of
Sham (Fig. 3.1A). Following PTX treatment, these catecholamine levels were decreased
significantly. However, the NE and EPI levels in the Sham rats treated with PTX were not
different from those of Sham operated rats.
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Fig.3.1. Assessment of Sympathetic Activity. (A) Norepinephrine (NE) and epinephrine (EPI)
levels in the plasma, samples were analysed using HPLC-ECD. ***p<0.001 (n=5 per group). (B)
Percent change in RSNA from baseline in rats in response to SNP IV bolus. (C) Percent change
in MAP from baseline in response to IV SNP bolus. Note that although IV SNP produced a
similar decrease in MAP between vehicle-treated Sham and CHF rats (respective baseline
values; 127.2 ±5.5 mmHg and 124.2 ± 4.1 mmHg), the magnitude increase in RSNA to IV SNP
was blunted in the CHF rats when compared to Sham rats. As compared to respective vehicle
treated groups, IV SNP produced a greater decrease in MAP in PTX-Sham and PTX-CHF
animals (respective baseline values; 112.0 ± 6.7 mmHg and 127.0 ± 4.1 mmHg, respectively). In
CHF rats, PTX treatment also augmented the baroreflex control of RSNA in response to IV SNP.
*p<0.05; **p<0.01 (n for Sham=9; Sham+PTX=5; CHF=6; CHF+PTX=11)

As shown in figures 3.1B and 3.1C, in Sham rats, IV SNP produced a marked decrease in
MAP and a concurrent increase in RSNA. The hypotensive and sympathoexcitatory responses to
IV SNP were further augmented in Sham rats treated with PTX. In CHF rats, IV SNP also
decreased MAP to a level similar to that observed in Sham rats; however, the magnitude increase
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in RSNA evoked by SNP at this dose was significantly blunted. Of merit, IP PTX treatment in
CHF rats not only enhanced the hypotensive response to IV SNP, but also augmented/restored
the renal sympathoexcitatory response to this hypotensive stimulus.
Effect of PTX Treatment on Cardiac Function and Morphology in HF. Compared to the
Sham rats, CHF rats demonstrated increased LVEDV, LVEDP, LV mass, mass/volume ratio and
Tei index, and a decreased SV, CO and EF. However, treatment with PTX attenuated only Tei
index. The carotid artery was catheterized to measure MAP and pulse pressure (PP). There were
no differences in the baseline HR, MAP and PP between Sham and CHF groups (Table 3.1).
Compared with Sham rats, CHF rats had increased right ventricle mass index and lung
mass index, which were decreased with PTX treatment, indicating less pulmonary vascular
congestion and hypertrophy. No significant difference was observed in the left ventricular mass
index.
Effect of PTX Treatment on Cytokine Expression Levels. As shown in figure 3.2, plasma
TNF- and IL-1β levels at 5 weeks remained at, or around, baseline levels during the entire
study in the Sham groups. In contrast, levels significantly elevated in the CHF group were
attenuated by PTX treatment.
At 5 weeks, the mRNA expression of TNF- (Fig. 3.3A) and IL-1β (Fig. 3.3B) was
significantly increased both in the LV and PVN of CHF rats. PTX treatment significantly
decreased these increased levels. PTX treatment in the Sham group had no effect on the
myocardial or PVN cytokine mRNA expression. Figure 3.3C illustrates that the elevated TNF-
protein levels in the LV and PVN, as analyzed by Western blot, were significantly attenuated by
PTX treatment.
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Table 3.1: Echocardiographic and Cardiac Morphological Parameters
Sham
Sham+PTX
CHF
CHF+PTX
Survival
PTX pre-treatment
n 7
7
14
15
24h survival 7 (100%)
7 (100%)
10 (71.4%)*
14 (93.4%)*,#
5-week survival 7 (100%)
7 (100%)
9 (64.8%)*
12 (80%)*,#
PTX post-treatment
n 7
7
10
10
24h survival 7 (100%)
7 (100%)
7 (70%)
7 (70%)
5-week survival 7 (100%)
7 (100%)
7 (70%)
7 (70%)
Echocardiography
n
7
7
10
10
HR (bpm)
415.2 ± 17.19
410.0 ± 4.88
407.0 ± 14.09
410.7 ± 16.42
MAP (mmHg)
1096
1087
1046
1025
PP (mmHg)
394
373
264*
272*
LVEDP (mmHg)
4.190.08
4.520.35
24.381.23*
14.172.7*,#
LVEDV (μl)
548.4 ± 88.56
517.3 ± 56.87
759.1 ± 24.3*
738.7 ± 52.49*
Mass (mg)
763.4 ± 58.23
807.8 ± 33.77
939.3 ± 28.76*
872.0 ± 46.0
Vol/Mass (μl/mg)
0.62 ± 0.09
0.52 ± 0.07
0.82 ± 0.03*
0.86 ± 0.08*
SV (μl)
473.2 ± 77.15
320.6 ± 41.5
261.7 ± 15.59*
250.6 ± 31.2*
CO (ml/min)
192.6 ± 22.0
157.3 ± 16.9
106.5 ± 7.7*
114.6 ± 16.3*
EF (%)
0.84 ± 0.01
0.82 ± 0.01
0.35 ± 0.02*
0.36 ± 0.03*
IZ (%)
0
0
54.42 ± 1.25*
56.26 ± 0.89*
Tei index
0.39 ± 0.01
0.40 ± 0.01
0.65 ± 0.02*
0.49 ± 0.02*,#
Morphology
Bodyweight (g)
36015
35923
35512
35318
LVM (mg)
0.87±0.03
0.88±0.05
1.000.08
0.950.07
LVMI (mg/g)
2.42±0.09
2.45±0.21
2.81±0.17
2.73±0.19
RVM (mg)
0.230.02
0.240.03
0.460.04*
0.350.04*,#
RVMI (mg/g)
0.64±0.09
0.67±0.07
1.31±0.15*
0.99±0.11*,#
LM (g)
1.490.064
1.520.09
4.530.31*
3.170.19*,#
LMI (mg/g)
4.15±0.13
4.23±0.10
12.78±0.84*
8.99±0.39*,#
Data are mean ± SEM. HR, heart rate; MAP, Mean arterial pressure; PP, Pulse pressure; LVEDV
and LVEDP, left ventricular end-diastolic volume and pressure, respectively; SV, Stroke
volume; CO, cardiac output; EF%, percent ejection fraction; IZ%, percent ischaemic zone; LVM
and RVM, left and right ventricular mass, respectively; LVMI and RVMI, left and right
ventricular mass index, respectively; LM, lung mass; LMI, lung mass index. Mass Index= mass
of the organ/body weight. *p<0.05 vs. Sham; #p<0.05 vs. CHF rats
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Fig.3.2. Plasma TNF-α and IL-1β levels from Sham and CHF rats Treated with Vehicle or
PTX. Data are mean ± SEM. ***p<0.001. For each group n=6.

Fig.3.3.
Expression
of
Cytokines in the LV and the PVN.
(A) mRNA expression of TNF-α in the
LV and the PVN as estimated by realtime RT-PCR. Values are mean ±
SEM. (n=6 per group) (B) mRNA
expression of IL-1β in the LV and the
PVN. Values are mean ± SEM. (n=6
per group) (C) Western blot analysis
of anti-TNF-α antibody in the LV and
PVN. Bar graphs are mean ± SEM
values of band intensities representing
four
independent
experiments.
**p<0.01; ***p<0.001
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Effect of PTX Treatment on AT-1R Expression. The AT-1R expression was increased
significantly in the LV and PVN of CHF rats compared to that of Sham rats, while treatment
with PTX restored these levels to normal (Fig. 3.4A). Similarly, the elevated protein levels of
AT-1R in the LV and the hypothalamus were restored to normal in PTX treated CHF rats (Fig.
3.4B).

Fig.3.4. AT-1R Levels in the LV and
the PVN. (A) AT-1R mRNA
expression in the LV and the PVN.
***p<0.001. (n=6 per group) (B)
Western blot analysis of anti-AT-1R
antibody in the LV and the
hypothalamus. Bar graphs are
mean ± SEM values of band intensities
representing
four
independent
experiments. *p<0.05; ***p<0.001

Effect of PTX Treatment on NOS Levels. The mRNA expression of iNOS was significantly
increased, while that of nNOS was significantly reduced in the PVN of CHF rats as compared to
those of Sham rats. PTX normalized the expression of iNOS and nNOS within the PVN of CHF
rats. No significant change in the nNOS expression was noticed in the PTX treated Sham rats
(Fig. 3.5).
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Figure 3.6A illustrates the PVN stained positive for NADPH-diaphorase activity. The
number of NOS-positive cells in the PVN of CHF rats was significantly less than that of the
Sham group. In CHF rats, treatment with PTX restored the number of nNOS-positive neurons in
the PVN to a level similar to that observed in the Sham group (Fig. 3.6B). Comparably, the
protein expression of nNOS, as determined by Western blot, showed a significant decrease in
CHF rats compared to both Sham rats and PTX treated CHF rats. PTX treated Sham rats showed
nNOS levels comparable to that of the vehicle treated Sham rats (Fig. 3.6C).
Immunohistochemical staining for nNOS protein showed that compared to Sham rats and PTX
treated CHF rats, a significant decrease in the number of neurons positively stained for nNOS
was observed in CHF rats (Fig. 3.6D).
Effect of Blockade of Cytokines on 3-nitrotyrosine (3-NT) Staining. Diffuse positive
immunostaining for 3-NT, an indicator of peroxynitrite, was observed in the surviving
cardiomyocytes of the peri-infarct region of the LV of CHF rats (Fig. 3.7A). The PVN of CHF
rats also demonstrated an increased staining for 3-NT (Fig. 3.7B and 3.7C). Treatment with PTX
significantly reversed these changes both in the LV and in the PVN of CHF rats.

Fig.3.5. mRNA Expression of iNOS and nNOS in the PVN. Values are means ± SEM. (n=6
per group). ***p<0.001
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Fig.3.6. Protein Expression of nNOS in the PVN. (A) nNOS activity detected by NADPH
diaphorase staining in the PVN of Sham, PTX treated and untreated CHF rats. (Magnification
shown 200X). (B) Quantification of nNOS positive neurons from the NADPH diaphorase
staining. Data are mean ± SEM. (n=10 per group). (C) Western blot analysis of anti-nNOS
antibody in the PVN. Bar graphs are mean ± SEM values of band intensities representing four
independent experiments. **p<0.01; ***p<0.001 (D) Immunostaining of the PVN for anti-nNOS
antibody (Magnification in the upper panel=400X; lower panel=200X).
DISCUSSION
The novel findings of the present study are 1) Pre-treatment with a cytokine blocker
improved survival and LV function in CHF rats; 2) CHF is associated with an increase in TNF-α
and IL-β, and a depletion of nNOS, within the PVN. Our molecular and biochemical findings
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indicate that blockade of cytokine production by treatment with PTX restored the nNOS levels in
the PVN and reduced sympathoexcitation in CHF; 3) AT-1 receptor levels were significantly
elevated in the PVN of CHF rats, but not in those treated with PTX, suggesting a cross-talk
between cytokines and the RAS in the PVN of HF rats.
Taken together, these results suggest that cytokines contribute to deleterious cardiac
effects and decreases in NO bioavailability in the PVN, contributing to enhanced
sympathoexcitation and poor survival rate, which is likely mediated via the AT-1R, ultimately
suggesting a cross-talk between cytokines and RAS.

Fig.3.7. Micrograph Showing Immunostaining for Anti-3-Nitrotyrosine in (A) the LV and
(B, C) the PVN. Note the evident increase in anti-3-NT signalling in the PVN of vehicle treated
CHF rats compared to those of Sham and PTX treated CHF rats.

Increased sympathetic activity (Aronson et al., 2002) and inflammatory cytokines
(Kowalewski et al., 2002) result in potentially serious ventricular arrhythmias, the main cause of
mortality in CHF. Our results demonstrate that the increased LVEDP, lung weight and right
ventricle mass in CHF were significantly lowered after PTX, indicating a selective effect on LV
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diastolic function which is comparable with decreased LVEDV. The increased Tei index in CHF
was also significantly decreased by PTX. These results indicate an improved LV diastolic and
systolic function. In addition, compared to the Sham group, CHF rats demonstrated a blunted
sympathoexcitatory response to IV SNP. This finding is consistent with the notion that in CHF,
there is an impaired baroreflex control of RSNA (Wang et al., 2003; Francis et al., 2004). Of
interest, IP PTX treatment in CHF rats enhanced not only the hypotensive response to IV SNP,
but also the magnitude of renal sympathoexcitation to this stimulus. These findings suggest that
in CHF, PTX treatment improved the baroreflex mechanisms that influence central
sympathoexcitatory outflow to the kidneys. Recent evidence also suggests that blocking the
production of cytokines in CHF rats, decreases sympathetic activity (Guggilam et al., 2007; Yu
et al., 2007). These adverse effects, including LV dysfunction and remodelling resulting in the
progression of HF, might be due to a sustained increase in TNF-α (Mann, 2002; Anker et al.,
2004). Thus, treatment with PTX improved cytokine-induced diastolic and systolic dysfunction
and reduced sympathetic hyperactivity resulting in improved LV function.
Nevertheless, more complex mechanisms are associated with increased sympathetic
activity in CHF than TNF-α alone. Recent studies underscore the importance of the interaction
between cytokines and the RAS in cardiac remodelling and increased sympathetic activity in the
progression of CHF. AngII and TNF-α can potentiate the effects of each other, resulting in a
vicious cycle towards CHF(Tsutamoto et al., 2000; Frolkis et al., 2001; Gurlek et al., 2001). The
brain RAS also plays an important role in sympathetic hyperactivity and cardiac remodelling in
CHF (Zucker et al., 2004). In the present study, treatment with PTX significantly decreased the
elevated expression of AT-1R in the heart and the PVN, improved LV function, and decreased
plasma catecholamines alongside a decrease in cytokine levels. These results further reinforce
the cross-talk between cytokines and AngII in the PVN in CHF.
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Besides its interaction with cytokines, AngII also interacts with NO in the PVN of CHF
animals. A reduction in NO in CHF may mediate an amplification of the AngII signal to further
increase sympathetic activity (Liu et al., 1998). Positive nNOS neurons of the PVN are important
in regulating central sympathetic outflow (Zhang et al., 2001) and increased sympathetic activity
in CHF is attributed, at least in part, by decreased nNOS neurons in the PVN (Zhang et al.,
1998). The blunted baroreflex in CHF also causes central AngII to augment sympathetic activity
in CHF (Barron et al., 1989). Apart from the intrinsic AngII of the brain, circulating AngII
molecules can cross the blood brain barrier (BBB) at the circumventricular organs (CVOs),
which express AT-1Rs and project multiple neurons into the PVN (McKinley et al., 1998). Upon
entry into the brain, these AngII molecules can potentiate the AT-1R as well as TNF-α
expression. In addition, MI-activated cytokines within the myocardium that exceeds the limit for
utilization by the local cellular receptors in autocrine/paracrine functions become blood-borne
and enter the systemic circulation. These cytokines enter the brain through a saturable transport
mechanism or a passive transport mechanism via the CVOs, further potentiating TNF-α and
AngII, while attenuating nNOS expression. Interestingly, results from the current study also
demonstrate that IP PTX treatment normalized the increased levels of AT-1R and decreased
levels of nNOS in the PVN of CHF rats, while improving the baroreflex control of RSNA to a
hypotensive stimulus. This clearly corroborates our hypothesis that a cross-talk exists between
cytokines, AngII and NO within the PVN, contributing to sympathoexcitation in CHF rats.
We also recently reported that increased oxidative stress in the PVN by cytokines is one
possible reason for increased sympathetic activity in CHF rats (Guggilam et al., 2007). ROSinduced cytotoxicity in the RVLM was shown to result in sympathoexcitation (Dawson et al.,
1996). AngII also exerts a positive feed-forward mechanism in the production of AngII and
superoxide, which are further sympathoexcitatory (Rajagopalan et al., 1996). The decreased
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nNOS expression, and the increased iNOS expression and formation of peroxynitrite in the PVN,
explain NO dysregulation in CHF rats. In the present study, treatment of CHF rats with PTX
decreased iNOS expression and prevented the formation of peroxynitrite, thereby reducing the
exaggerated sympathetic activity in CHF.

Fig 3.8. Mode of Action of TNF-α in Modulating ROS Production in the PVN and
Contributing to Sympathoexcitation. The MI-activated cytokines in the myocardium that
become blood-borne, as well as the sympathetic afferent activation, potentiate the expression of
TNF-α in the PVN that in turn up-regulates AT-1R expression in the PVN. TNF-α and AngII
feed forward each others’ effects in the PVN, and together contribute to increased superoxide
and decreased bioavailability of NO via peroxynitrite (ONOO·) formation, thus contributing to
impaired baroreflex sensitivity and increased sympathoexcitation, ultimately resulting in LV
dysfunction.
In addition to the blood-borne cytokines crossing the BBB, cardiac sympathetic afferents
also activate hypothalamic synthesis of cytokines in rats (Francis et al., 2004). Similarly, the
elevated AT-1R expression in the heart and PVN suggests that both peripheral and central AngII
could possibly play a role in depleting nNOS positive neurons in the PVN, possibly via
sympathetic afferents. Restoration of nNOS levels by treatment with a cytokine blocker indicates
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a cross-talk between cytokines, AngII and NO. This ultimately implies that cytokines might
decrease NO either directly, or indirectly, via a pathway involving the AT-1R, the action of
which results in sympathetic hyperactivity in CHF (Figure 3.8).
There are a few limitations to this study. In addition to blocking cytokines PTX has a
positive inotropic effect on the heart; it is not known at this point whether the effects exerted by
PTX are by virtue of its phosphodiesterase inhibitory activity. Nevertheless, we chose this drug
due to its effect as a general cytokine blocker. The concept we are introducing in this study is
that there is an interaction between cytokines, RAS and nitric oxide in the sympathoexcitatory
process observed in CHF. Clearly, further studies are required to specifically delineate the
mechanism by which the RAS and NO system interact within the neurons of the PVN in the
presence or absence of cytokines.
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CHAPTER 4
TNF CONTRIBUTES TO SYMPATHOEXCITATION IN HEART FAILURE THROUGH
MODULATION OF SUPEROXIDE AND NITRIC OXIDE IN THE CENTRAL NERVOUS
SYSTEM
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INTRODUCTION
Recent studies underscore the importance of central nervous system mechanisms in the
regulation of blood pressure and cardiovascular homeostasis. It is well known that increased
sympathoexcitation after myocardial infarction (MI) is the major cause of progression of this
disease. Elevated tumor necrosis factor (TNF), along with other circulating hormones such as
angiotensin II (AngII), in heart failure are typically transported into the brain via the
circumventricular organs (CVOs), areas that lack a well formed blood brain barrier (BBB). Once
through the BBB, AngII acts in the paraventricular nucleus (PVN) of the hypothalamus to
regulate thirst, salt appetite and sympathetic nerve activity, primarily mediated through reactive
oxygen species (ROS) production (Zimmerman et al., 2002; Zimmerman et al., 2004; Campese
et al., 2005). Our previous study showed that in congestive heart failure (CHF), the increased
TNF is related to increased NADPH oxidase subunit expression, the primary source of
superoxide anions (O2•−), within the PVN (Guggilam et al., 2007). Moreover, blockade of O2•− in
the PVN completely abolished the increased sympathetic activity associated with CHF (Han et
al., 2007). AngII-induced ROS in the rostral ventrolateral medulla (RVLM), an important
autonomic regulatory center, also plays a key role in the modulation of sympathetic nerve
activity and cardiovascular function (Mayorov et al., 2004; Gao et al., 2005). Blockade of AngII
type-1 receptors (AT1Rs) in the PVN (Han et al., 2007) and RVLM attenuated generation of
ROS, contributing to decreased sympathetic activity in CHF. In addition, systemic AT1R
blockade can decrease the production of TNF, thus limiting cardiac remodeling and dysfunction.
However, the importance of central TNF in increased sympathoexcitation is not completely
understood.
Recently we reported that the decreased neuronal nitric oxide synthase (nNOS), a
primary source of nitric oxide (NO) in the PVN, is attenuated in CHF animals treated with
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pentoxifylline, a TNF inhibitor (Guggilam et al., 2008). It is well known that decreased NO
production in CHF is associated with increased sympathoexcitation. AngII plays a role in the
modulation of NO, which acts, in part, in the production of ROS. Intracerebroventricular (ICV)
administration of AngII can decrease nNOS, with its concurrent increase in ROS, in the PVN,
ultimately leading to increased sympathetic activity (Campese et al., 2002; Campese et al.,
2005). However, after myocardial infarction (MI), elevation of TNF has been observed even
before that of neurohormones, including AngII. Therefore, it is possible that the increased TNF
observed following MI can trigger the production of other peptides that lead to neurohumoral
excitation. To date, the importance of central TNF in increased sympathoexcitation is not
completely understood.
We, therefore, hypothesized that TNF induces O2•− and modulates NO in the PVN and
RVLM, possibly through AT1R activation, and contributes to sympathoexcitation in CHF. To
explore our hypothesis, we used two approaches: 1) chronic central blockade of TNF with
etanercept (ETN, a human recombinant TNF receptor fusion protein that competitively binds
with TNF, thereby preventing the binding of TNF to its receptor) in heart failure mice; 2) whole
body TNF gene knockout (TNF KO) mouse model to study the role played by TNF in body fluid
homeostasis and sympathoexcitation in heart failure. We also explored the interaction between
O2•− and NO in the PVN and RVLM and its contribution to sympathoexcitation in heart failure.
The results of this study provide insight into the mechanisms that induce sympathoexcitation and
disease progression in the failing heart.
METHODS
Mice. Male TNF KO (B6;129S-Tnftm1Gkl/) and wild-type (WT) mice (Jackson Laboratory, ME)
of 12-16 weeks of age with similar B6129SF2/J genetic background were used in the present
study. Mice were housed in a light (12 h light-dark cycle) and temperature-controlled room and
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standard chow and water were provided ad libitum. All surgical procedures in animals were
performed at Louisiana State University School of Veterinary Medicine and were carried out in
accordance with the regulations of the Louisiana State University Animal Care and Use
Committee and conforms with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Drugs. Etanercept (Enbrel) was purchased from Amgen and Wyeth Pharmaceuticals
(Collegeville, PA). The drug was dissolved in artificial cerebrospinal fluid (aCSF) for ICV
infusion. The dose used in this study was optimized by preliminary experiments conducted in our
lab.
Experimental Protocol and Surgical Procedures. To explore our hypothesis, the study was
conducted in two protocols. In protocol I, we studied the effect of central blockade of cytokines
on sympathoexcitation. In this protocol, WT mice had a cannula implanted into their right lateral
cerebral ventricle, using the following stereotaxic coordinates: 0.3mm posterior to bregma,
1.0mm lateral from midline and 2.8mm from the surface of the skull. After one week of
recovery, they underwent either coronary artery ligation to induce MI or sham surgery. While
still under anesthesia, an 28-day osmotic minipump (Alzet) was implanted subcutaneously on the
back of the neck. The minipump was connected to the cannula in the lateral ventricle for
continuous infusion (0.11μl/hr) of ETN (5µg/hr) or vehicle (VEH; aCSF) over a 4-week
treatment interval.
In protocol II, we used TNF KO mice, along with WT mice, to study the effect of TNF
gene ablation on sodium and fluid retention and subsequent sympathoexcitation. In this phase,
mice were acclimated in custom designed metabolic cages for one week. The mice then
underwent coronary artery ligation and thereafter were maintained in metabolic cages with free
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access to food, water and 1.8% NaCl solution. Water and salt intake were measured and 24 hurine collections were obtained for the duration of the study.
At the end of the study, mice from both protocols were anesthetized and sacrificed by
decapitation. Blood samples were collected for plasma norepinephrine (NE) measurement.
Hypothalamus and brainstem samples were collected for gene expression studies. Mice that were
used for ESR studies were injected with heparin (100U/25 g body wt.) and then perfused
transcardially with ice-cold buffer, and these brain regions were collected and processed for ROS
measurement. For immunofluorescence studies, anesthetized mice were perfused transcardially
with ice-cold heparinized saline, followed by formalin. The tissues were stored in formalin until
further processed.
Surgical Procedures
ICV Cannula: Mice were anesthetized with ketamine/xylazine (80 mg/kg ketamine+10 mg/kg
xylazine, I/P). Following placement into the stereotaxic apparatus (Kopf instruments, CA), an
incision was made through the skin, fascia was removed and the skull was exposed. After the
skull was leveled in the rostral/caudal direction, a small, stainless steel screw was inserted into
the skull and the cannula was inserted through a drilled hole at the position previously
mentioned. Dental acrylic was used to fix the cannula in place and the skin was sutured over the
hardened dental acrylic cap. Mice were treated with analgesics and allowed to recover for 1 week
before induction of myocardial infarction.
Experimental Myocardial Infarction (MI): Mice were premedicated with atropine sulfate
(0.04 mg/kg SC) and anesthetized 5 min later with 2% v/v isoflurane/oxygen. Mice were placed
on a heating pad in supine position and the trachea was intubated using a 24-guage intravenous
catheter with a blunt end. Anesthesia was maintained by supplementing oxygen (1.8 L/min) and
0.7%-2.0% isoflurane at a rate of 105/min and with a tidal volume of 2.1-2.5 ml using a rodent
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ventilator (Harvard Apparatus, Inc., MA). A left lateral thorocotomy was performed by blunt
incision in the fourth intercostal space, the left anterior descending (LAD) coronary artery was
ligated using a prolene monofilament with tapered needle (Ethicon USP 7-0, Johnson & Johnson
Co., NJ) 2-3 mm from the tip of the left auricle with the aid of a dissecting microscope (Zeiss) to
induce MI. After coronary artery ligation (CAL), the chest was closed, and the mouse was
allowed to recover. In sham-operated animals, the suture was placed under the LAD artery and
removed without ligation of the vessel. Operated mice were monitored and studied for a period
of 5-weeks following surgery.
Osmotic Mini-pump Implantation: Immediately following MI, while still under anesthesia, a
subcutaneous incision was made upon the back of the mouse, a pocket was made between the
skin and muscle and washed with sterile saline. Single 28-day osmotic mini-pumps with
polyvinyl tubing (0.027”I.D. x 0.045”O.D.) attached to the pump injector were implanted in each
mouse. The tubing was inserted under the skin and connected to the cannula in the lateral
ventricle and fixed into place with dental acrylic cement. The skin incision was closed and the
mice were treated with analgesics.
Metabolic Studies. To study relative fluid and sodium balances among different treatment
groups, we performed metabolic studies by placing animals in custom-designed individual
metabolic cages with free access to food, water and 1.8% NaCl solution, in a temperaturecontrolled environment and a 12/12 h light–dark cycle. Three days after acclimation, water and
salt solution intake were measured and 24 h-urine collections were obtained for the duration of
the study. Sodium intake (mEq) was calculated as salt solution intake multiplied with salt
content/equivalent weight of sodium. All sodium chloride is expressed as sodium. Urine samples
were collected under saturated oil in graduated conical tubes to avoid evaporative losses and
their volumes recorded. All aliquots of urine were immediately frozen at -20°C until urinary
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sodium (UNa) was determined by a Nova electrolyte 16+ analyzer (Nova Biomedical, Waltham,
MA). Total 24 h UNa excretion was calculated by multiplying the measured concentration with
the daily urine volume.
Echocardiography. Cardiac function and development of CHF were analyzed by
echocardiography 24 h and 4- weeks after induction of MI. Echocardiography was performed in
mice anesthetized with 1.5% isoflurane/oxygen with Toshiba Aplio SSH770 system (Toshiba
Medical Systems, CA) fitted with a PLT 1202 linear transducer (12 or 14 MHz), which generates
two-dimensional images at frame rates ranging from 300 to 500 frames per second. Left
ventricular (LV) wall thickness, LV end-diastolic dimension (LVD), LV end-systolic dimension
(LVS), LV end-systolic posterior wall thickness (PWS), and LV end-diastolic posterior wall
thickness (PWD) were measured using two-dimensional short-axis imaging. LV percent
fractional shortening (%FS) was calculated as: %FS = (LVD – LVS)/LVD x100%. The portion
of the LV that displays akinesis was electronically planimetered and expressed as a percent of the
total LV silhouette to estimate the size of the infarct. Only the mice that had an infarct size of 4050% were used for the study.
Semi-quantitative Real-time RT-PCR. RNA was isolated from hypothalami and brainstems
with TRIzol (Invitrogen, CA), treated with DNAase, and reverse transcribed using random
primers reverse transcriptase. Gene transcripts were determined by quantitative real-time
polymerase chain reaction using SYBR-Green master mix (Applied Biosystems, CA) on an
Applied Biosystems 7900. Gene expression levels were calculated using the 2-∆∆Ct method and
normalized to 18S gene. The level of change was expressed as fold change versus respective
sham values.
Electron Spin Resonance (ESR) Studies. One of the most sensitive and definitive methods of
measurement of superoxide production is electron spin resonance (ESR). In this study, we
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utilized an established technique for superoxide anion (O2•−) and OONO• measurement in the
hypothalamus/brainstem using ESR and the spin trap. Two different spin probes were used for
ESR studies. 1-hydroxy-3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) was used
to measure O2•− levels, and 1-hydroxy-3-carboxypyrrolidine (CPH) was used to measure
peroxynitrite (OONO•) levels. All ESR measurements were performed using an EMX ESR
eScan BenchTop spectrometer and super-high quality factor (Q) microwave cavity (Bruker
Company, Germany).
Sample Preparation for ESR Studies: The dissected hypothalamus/brainstem from each
animal was placed into a 24-well plate containing Kreb’s HEPES buffer (KHB) (20mM, pH 7.4)
Tissue pieces were then washed twice with the same buffer to remove any trace contamination.
Samples were then incubated at 37oC with specific spin probes for 30 minutes.
Total Tissue O2•− Production: Tissue pieces were incubated at 37oC with CMH (200 μM) for
30 minutes. Aliquots of the incubated probe media were then taken in 50 μl glass capillary tubes
(Noxygen Science Transfer and Diagnostics, Elzach, Germany) for determination of total ROS
production, under the following ESR settings: field sweep 50 G; microwave frequency 9.78
GHz; microwave power 20 mW; modulation amplitude 2 G; conversion time 327 ms; time
constant 655 ms; receiver gain 1 x 105. For superoxide production, samples were pre-incubated
at 37oC with PEG-SOD (50 U/ml) for 30 minutes, then CMH (200uM) for an additional 30
minutes. Aliquots of the incubated probe media were taken in 50 μl glass capillary tubes for
determination of total superoxide production. Addition of PEG-SOD to CMH allowed
competitive inhibition of the O2•−-CMH oxidation reaction by the quenching of O2•− radicals.
Since it is cell permeable, PEG-SOD can competitively inhibit the CMH-O2•− interaction both
intracellularly and extracellularly, thus allowing accurate measurement of total tissue O2•production. To determine actual total tissue superoxide production, the values obtained from
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incubation with PEG-SOD and CMH were subtracted from the values obtained from incubation
with CMH only.
Tissue OONO• Production: Tissue pieces were incubated at 37oC CPH (500 μM) and the
reaction was initiated by adding cysteine (100uM) for 30 minutes. The reaction of OONO• with
the thiols of free cysteine is the first direct reaction of OONO•, and cysteine is the amino acid
that reacts the fastest with peroxynitrite. Aliquots of the incubated probe media were then taken
in 50 μl glass capillary tubes for determination of OONO• production following the parameters
previously outlined.
Double-labeling Immunofluorescence. Fluorescent immunohistochemistry was performed as
described previously (Khaleduzzaman et al., 2007) with minor modifications. The anesthetized
mice were perfused transcardially with heparinized saline followed by 10% neutral buffered
formalin. Brains were then collected and stored in 4% paraformaldehyde until analyzed. The
brains were embedded in paraffin and 10 µm thick sections were cut on Superfrost plus slides
(Fischer scientific) and incubated overnight at 56˚C. The slides were then deparaffinized in
xylene, and rehydrated in descending grades of ethanol. Antigen retrieval was performed by
incubating slides in Reveal decloaker, pH 6.0, for 30 min at 120°C in a decloaking chamber
(Biocare Medical, Concord, CA) at 17 to 19 lb/in2 and cooled to 90°C. Following equilibration to
RT, slides were incubated in 0.2% fish skin gelatin (FSG) (Sigma-Aldrich, St. Louis, MO) in
PBS for 10 min. This solution was also used to wash slides between all incubations. Tissues were
blocked in a humidity chamber for a minimum of 30 min with blocking solution consisting of 2%
donkey serum (Sigma), 1% bovine serum albumin (BSA) (Sigma), 0.05% FSG, 0.1% Triton X100 (Sigma), and 0.05% Tween 20 (Bio-Rad) in PBS. To identify neuronal cells, the slides were
incubated overnight at 4°C with a 1/100 dilution of mouse polyclonal anti-neuronal nuclear
protein (NeuN) (Molecular Probes). Slides were then incubated with 1/300 dilution of
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biotinylated mouse anti-goat immunoglobulin G (IgG) or goat anti-rabbit IgG (Molecular Probes)
for 30 min at RT and then incubated with 1/500 dilution of streptavidin conjugated to Alexa
Fluor 594 (Invitrogen).
For dual staining, slides were incubated in blocking solution for 30 min, incubated with
rabbit polyclonal anti-nNOS or anti-3-nitrotyrosine (3-NT) or an antibody that recognizes c-Fos,
FosB, Fra-1, or Fra-2 (c-Fos K25, Santa Cruz) in 0.2% FSG in PBS at 4°C overnight. Slides were
then incubated with 1/300 dilution of biotinylated goat anti-rabbit IgG (Molecular Probes) for 30
min at RT and then incubated with 1/500 dilution of streptavidin conjugated to Alexa Fluor 488
for 30 min at RT. Slides were mounted with ProLong Gold antifade reagent (Molecular Probes)
and allowed to set for overnight at 4°C. The lack of nonspecific staining was confirmed by using
no primary antibody controls (data not shown).
Data Analyses. All data illustrated are expressed as mean ± SEM. Statistical analyses were
performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, CA,
www.graphpad.com. Log-rank (Mantel-Cox) test was used to compare the survival rates between
groups. Student’s t-test was used to compare the fold changes in mRNA levels between WT+MI
and TNF KO+MI groups. One-way ANOVA was used to observe the differences among groups,
and two-way ANOVA or ANOVA with repeated measures was used comparison of metabolic
parameters, followed by Bonferroni’s correction. Spearman’s correlation was used to measure
the strength of the relationship between 24-h sodium excretion and calculated daily sodium
intake. Survival rates were compared using log rank test. In all cases, p<0.05 was considered
statistically significant.
RESULTS
Improved Survival in TNF KO Mice After MI. In protocol I, within the first one week, 33.3%
mortality was observed in MI+VEH mice, while the mortality rate was reduced to 10% in mice
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treated centrally with TNF blocker (MI+ETN mice) (Figure 4.1A). In protocol II, within 24 h
after CAL surgery, <5% mortality was observed in both TNF KO and WT sham mice. At the end
of the study, the mortality was 20.1% in WT+MI mice while the mortality was 6.7% TNF
KO+MI mice. Most deaths occurred within the first 10 days and were a result of cardiac rupture
as determined by findings at autopsy. However, compared to the Sham mice, significantly more
WT+MI mice (p=0.0054) died during the study than the TNF KO+MI mice (p=0.15) (Figure
4.1B).

Figure 4.1 Kaplan–Meier Survival Curve in WT and TNF KO Mice at the End of the
Study. (A) Survival rate was improved in CHF mice treated with ETN compared to those treated
with VEH. (B) The WT mice with CHF exhibited a significant (**, p < 0.01) decrease in survival
compared with sham-operated WT and TNF KO mice 4wks after MI. TNF KO mice
demonstrated significantly (#, p<0.05) greater survival compared with WT 4wks after MI.

Decreased Fluid and Sodium Retention in TNF KO Mice. Figure 4.2 shows the effect of TNF
on fluid intake, urine output (UO), sodium intake and sodium excretion (UNa) in WT and KO
mice. Water intake was significantly decreased, while salt or sodium intake was dramatically
increased by day 2 and day 3 in WT+MI mice. After day 3, water intake remained constant in all
the experimental groups, while sodium intake by hypertonic saline drinking remained elevated in
WT+MI mice throughout the study, but not in the Sham or TNF KO+MI mice. UO and UNa were
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significantly decreased in WT+MI mice. On the contrary, the UO and UNa tended to decrease till
day 3 but later returned to be in line with those of sham-operated WT and TNF KO mice. In this
study, dietary sodium intake was not considered as there was no significant difference in food
intake among different groups.
In sham-operated WT and TNF KO mice, the correlation coefficient between daily
sodium intake and UNa excretion was 0.26 (p=0.24) and -0.24 (p=0.27), respectively. However,
the corresponding correlation coefficients for WT and TNF KO heart failure mice were -0.82
(p<0.0001) and 0.66 (p<0.01), respectively.
Improved Cardiac Function in TNF KO Mice After MI. Echocardiography revealed an
improvement in the %FS after 4wk ETN treatment, while no improvement in %FS was observed
in VEH-treated heart failure mice (Table 4.1). CHF was associated with marked decrease in
percent fractional shortening at 4-weeks in WT+MI mice compared to that of TNF KO+MI mice
(Table 4.2). However, no significant difference was observed in LV dimensions over the 4wk
period, which might be due to the large infarct size in these mice.
Heart and lung weights were measured at the end of the 4-week study (Figure 4.3).
Compared to the WT+Sham mice, the wet lung weight ratios, but not the heart weight ratios,
were significantly higher in the WT+MI mice, suggesting development of pulmonary congestion.
We did not observe any difference among their heart weight ratios possibly because of the infarct
size. On the contrary, lung weights in TNF KO+MI mice were significantly lower than those in
the WT +MI mice with similar infarct size, indicating decreased pulmonary congestion with TNF
ablation.
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Figure 4.2 Metabolic Parameters. Daily water intake (A), sodium intake (B), urine output (C),
and sodium excretion (UNa) (D) of WT and TNF KO mice during the first 3wks after MI or sham
surgery. Data are presented as means±SEM.

Table 4.1: Echocardiographic Findings in Mice from Protocol I
Sham

MI+VEH

MI+ETN

24h

4wk

24h

4wk

24h

4wk

IVSS

1.33±0.02

1.41±0.09

1.18±0.11

1.13±0.14

1.25±0.24

1.18±0.13

IVSD

0.84±0.03

0.88±0.05

0.67±0.04

0.74±0.04

0.69±0.04

0.63±0.06

LVS

3.04±0.16

3.21±0.28

2.61±0.42

3.21±0.30

2.95±0.19

3.27±0.92

LVD

4.40±0.11

4.50±0.15

4.03±0.38

4.76±0.32

4.03±0.22

4.75±0.57

PWS

1.33±0.07

1.05±0.06

1.28±0.07

1.21±0.10

1.20±0.06

1.16±0.10

PWD

0.84±0.07

0.82±0.04

0.80±0.07

0.74±0.05

0.78±0.05

0.86±0.29

%FS

32.76±2.83 33.58±0.94 36.37±2.18 27.13±1.20** 34.89±1.17 44.23±3.80*

Data are mean±SEM. IVD and IVS, left ventricular internal diameter at end-systole and enddiastole, respectively; LVD and LVS, left ventricular septal thickness at end-diastole and endsystole, respectively; PWD and PWS, posterior wall thickness at end-diastole and end-systole,
respectively; %FS, fractional shortening. (*, p<0.05; **, p<0.01)
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Table 4.2: Echocardiographic Findings in Mice from Protocol II
WT

TNF KO

MI 24h

MI 5wk

MI 24h

MI 5wk

IVSS

1.01±0.08

1.26±0.15

1.03±0.08

1.02±0.06

IVSD

0.69±0.02

0.78±0.07

0.61±0.03

0.69±0.04

LVS

3.17±0.04

2.99±0.18

3.11±0.26

2.95±0.18

LVD

4.21±0.07

4.41±0.08

4.16±0.23

3.96±0.20

PWS

1.04±0.07

1.21±0.08

1.05±0.06

1.08±0.05

PWD

0.68±0.05

0.83±0.08

0.66±0.04

0.70±0.03

%FS

34.60±1.46 25.23±0.79* 25.89±2.48 25.59±1.92

Data are mean±SEM. IVD and IVS, left ventricular internal diameter at end-systole and enddiastole, respectively; LVD and LVS, left ventricular septal thickness at end-diastole and endsystole, respectively; PWD and PWS, posterior wall thickness at end-diastole and end-systole,
respectively; %FS, fractional shortening. (*, p<0.05; **, p<0.01)

Figure 4.3 (A) Heart weight/body weight ratio of WT, ETN-treated and TNF KO mice 4wks
after sham or CAL. (B) Lung weight/body weight ratio of WT, ETN-treated and TNF KO mice
4wks after sham or CAL. WT+CHF mice exhibited significantly greater fluid accumulation in
the lungs as compared with TNF KO+CHF.
(*, p<0.05; **, p<0.01)
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Altered Cytokine Expression in the Hypothalamus and Brain Stem in CHF. The increases in
transcript levels of TNF, IL-1β and IL-6 were significantly higher in the hypothalamus and
brainstem of MI+VEH compared to MI+ETN mice indicating that blocking TNF centrally
results in the decreased production of other pro-inflammatory cytokines in these cardiovascular
regulatory centers. Compared to the TNF KO+MI mice, these levels were higher in WT+MI
mice. On the contrary, WT+MI mice demonstrated a decrease in IL-10, an anti-inflammatory
cytokine, and this was restored in MI+ETN and TNF KO+MI mice (Table 4.3).
Altered Expression of O2•− and NO Sources in the Hypothalamus and Brain Stem in CHF.
The expression of Nox2 and Nox4, homologues of the major catalytic subunit of NADPH
oxidase, were up-regulated both in the hypothalamus and brainstem regions of MI+VEH
compared to the ETN-treated mice. These levels were also higher in WT+MI mice compared to
the TNF KO+MI mice (Table 4.3). These findings are consistent with the O2•− production
observed in the PVN and VLM regions (Figure 4.4).
The expression of nNOS was decreased, while that of inducible NOS (iNOS) was
increased in the hypothalamus and brainstem of MI+VEH mice as well as WT+MI mice
compared to that of ETN-treated or sham-operated/TNF KO+MI mice, respectively (Table 4.3).
Immunofluorescence studies demonstrated a significant decrease in the number of nNOSpositive neurons in the VLM of WT+MI mice as compared to both of the sham-operated groups.
Neurons were identified by co-staining with the neuronal marker NeuN. In the VLM of TNF
KO+MI mice, the number of nNOS-positive neurons was not different from that of TNF+Sham
mice (Figure 4.5). We observed a similar pattern of nNOS expression in the PVN (Data not
shown).
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Table 4.3. Gene Expression of Cytokines, Nitric Oxide Synthases, Nox Homologues, and AngII Receptors in the Hypothalamus
and Brainstem of WT and TNF KO Mice at 4wks following MI.
Category

Transcript

Hypothalamus

Brainstem

MI+VEH

MI+ETN

TNF KO+MI

MI+VEH

MI+ETN

TNF
KO+CHF

TNF

2.38±0.09

0.40±0.34*

0.88±0.06*

2.01±0.17

0.81±0.85*

1.15±0.09

IL-1β

3.73±0.06

1.30±1.72*

1.52±0.43*

2.81±0.36

1.96±1.00

1.39±0.29*

IL-6

1.64±0.11

1.08±0.38

0.96±0.08

1.38±0.14

1.02±0.31

1.11±0.18

IL-10

1.11±0.08

4.31±1.96*

3.13±0.66*

0.53±0.03

2.21±1.71*

1.01±0.13*

nNOS

0.59±0.09

1.27±0.22

1.84±0.11*

0.69±0.09

1.26±0.42*

1.66±0.36*

eNOS

0.90±0.10

1.20±0.05*

1.94±0.25*

1.07±0.07

1.26±1.13

1.76±0.20

iNOS

2.57±0.12

0.98±0.06*

0.75±0.05*

0.90±0.19

1.24±0.16

0.63±0.06

Nox2

3.08±0.38

1.44±1.00*

1.21±0.24*

1.96±0.25

1.88±0.23

0.80±0.17*

Nox4

1.58±0.15

0.99±0.08*

0.84±0.12**

1.28±0.11

1.03±0.07

0.78±0.04**

AT1R

1.96±0.19

0.92±0.12*

0.64±0.09**

1.79±0.03

1.04±0.16

0.76±0.03**

AT2R

0.86±0.09

1.56±0.04*

1.97±0.26*

0.81±0.09

1.28±1.17

1.42±0.07**

Cytokines

Nitric oxide
synthases

Nox homologues

AngII receptors
Values expressed are means±SEM of fold change (2-∆∆Ct) versus respective Sham group. (*, p<0.05; **, p<0.01)
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TNF Plays a Role in the Interaction between O2•− and NO in CHF. To assess the interaction
between O2•− and NO in the PVN and VLM regions, we used immunofluorescence co-staining
with 3-NT, a product of OONO•, and nNOS. The percent nNOS-positive cells that stained for 3NT were comparatively higher in the PVN after 4-weeks of MI in both WT and TNF KO mice
compared to their respective sham-operated groups. However, the number of 3-NT-positive
neurons was significantly higher in the WT+MI mice compared to the TNF KO+MI (Figure 4.6).
Similar effects with regard to nNOS and 3-NT expression were seen in the VLM region of WT
and TNF KO mice with/without CHF (Data not shown).
We further confirmed the formation of OONO• in PVN and VLM by ESR. CHF resulted
in increased OONO• levels in these brain regions in ICV ETN-treated mice compared to that of
VEH-treated mice (Figure 4.5). In addition, significantly higher OONO• production was
observed in WT mice compared to TNF KO heart failure mice (Figure 4.5). Although O2•− and
OONO• are produced in other brain regions, only the PVN and VLM showed significant
differences in CHF and sham mice. Therefore, quantitative analyses presented are focused on
these regions.
TNF Alters Angiotensin Receptor Expression in the Hypothalamus and Brainstem in CHF.
We observed a decrease in AT1R expression in the hypothalamus and brainstem of heart failure
mice treated ICV with ETN compared to those of VEH-treated mice (Table 4.3). CHF also
induced a significant increase in the AT1R expression in the hypothalamus and brainstem of WT
mice over TNF KO mice (Table 4.3). On the contrary, CHF induced a marked decrease in the
expression of AT2R in these brain regions in WT mice compared to TNF KO mice (Table 4.3).
No difference was observed in the expression of these receptors in sham-operated mice.
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Figure 4.4. (A) Superoxide anion and (B) peroxynitrite production in the PVN of mice 4wks
after MI. (C) Superoxide anion and (D) peroxynitrite production in the VLM of mice 4wks after
MI. (*, p<0.05; **, p<0.01; ***, p<0.001).

Neuronal and Sympathoexcitation Attenuated with TNF Ablation in CHF. Chronic neuronal
activation in the PVN and VLM was studied by using an antibody that detects all members of the
Fos family; c-Fos, FosB, Fra-1 and Fra-2. As shown in representative photomicrographs in figure
4.7A, CHF induced a markedly greater number of Fos-positive neurons in WT mice compared to
the TNF KO mice. It should be noted that in sham-operated mice, the number of Fos-positive
neurons were not different from each other (Figure 4.7B).
As shown in figure 4.7C, the plasma NE levels, an indirect indicator for
sympathoexcitation, were significantly elevated in MI+VEH and WT+MI mice. However, in
ETN-treated, sham-operated as well as TNF KO+MI mice, this increase was attenuated.
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Figure 4.5. (A) Double-immunofluorescence histochemistry for NeuN, a marker for neuronal
nuclei (left panel), nNOS (center panel), and their overlay (right panel) in the VLM. NeuN and
nNOS were labeled with AlexaFluor 594 and AlexaFluor 488, respectively. Scale bar: 50 μm.
(B) Total number of nNOS+ cells are lower in WT+CHF group (***, p<0.001) compared with
WT+Sham. There is no difference in the nNOS+ neurons in TNF KO mice 4wks after MI.
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Figure 4.6. (A) Double-immunofluorescence histochemistry for 3-NT (left panel), nNOS (center
panel), and their overlapping (right panel) in the PVN. 3-NT and nNOS were labeled with
AlexaFluor 594 and AlexaFluor 488, respectively. Scale bar: 50 μm. (B) Total number of 3-NT+
cells are higher in WT+CHF group (***, p<0.001) compared with WT+Sham. There is no
difference in the 3-NT+ neurons in TNF KO 4wks after MI compared with sham mice.
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Figure 4.7. (A) Double-immunofluorescence histochemistry for NeuN (left panel), Fos (center
panel), and their overlapping (right panel) in the PVN. NeuN and Fos were labeled with
AlexaFluor 594 and AlexaFluor 488, respectively. Scale bar: 50 μm. (B) Total number of Fos+
cells are higher in WT+CHF group (***, p<0.001) compared with WT+Sham. There is no
difference in the Fos+ neurons in TNF KO mice 4wks after MI compared to sham mice. (C)
Plasma NE levels were significantly higher in WT mice compared with TNF KO mice 4wks
after MI.
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DISCUSSION
The present study highlights several important findings: 1) central administration of an
anti-TNF agent reduces NADPH oxidase subunit expression, ROS production and decreases
sympathoexcitation in the presympathetic regions of the brain; 2) increased sodium and fluid
retention observed in CHF are partly dependent upon elevated cytokine levels; 3) central TNF
blockade as well as knocking out the TNF gene elevates the reduced nNOS expression in the
PVN and VLM in CHF; and 4) blocking TNF reduces OONO• formation and reduces neuronal
excitation in CHF. These findings support our hypothesis that the resultant sympathetic
hyperactivity in CHF is due to TNF-induced oxidative stress in the sympathoexcitatory neurons
of the PVN and VLM.
Our previous studies indicate that systemic administration of anti-cytokine agents can
lower brain pro-inflammatory cytokine synthesis, NADPH oxidase subunit expression and
superoxide production in CHF (Guggilam et al., 2007). The present study, demonstrating that
central cytokine inhibition reduces ROS production in the PVN and VLM regions resulting in
reduced neurohumoral excitation, strongly indicates that central TNF levels are intrinsically
involved in NADPH oxidase activation, ROS production and sympathoexcitation seen in CHF. A
recent study showed that subchronic ICV infusion of AngII induced O2•− production in the
RVLM is associated with elevated basal RSNA and impaired arterial baroreflex function (Gao et
al., 2005). Moreover, bilateral microinjections of tempol or tiron into the RVLM attenuated the
pressor, sympathetic, and tachycardic responses to microinjection of AngII into the RVLM
(Mayorov et al., 2004). These studies show that ROS in the RVLM play an important role in the
modulation of sympathetic activity and cardiovascular function by central AngII (Gao et al.,
2005). Interestingly, the O2•− source in all the above cases appears to be from NADPH oxidase.
Consistent with these findings, in the present study, the expression of the catalytic subunits of
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NADPH oxidase, Nox2 or Nox4, were significantly elevated in CHF in the hypothalamus and
brainstem of mice treated ICV with the TNF antagonist ETN. The attenuated O2•− levels in CHF
in the PVN and VLM of ETN-treated mice clearly delineates the role of TNF in CHF-induced
ROS production. These findings were further confirmed in a TNF gene knockout model.
Another important function of AngII in the hypothalamus is the activation of arginine
vasopressin in contributing to the CHF syndrome through increased thirst and sodium appetite
(McKinley et al., 2001). In addition, the drinking behavior of mice in response to AngII infusion
was shown to be mediated via NADPH oxidase induced superoxide production (Zimmerman et
al., 2002; Zimmerman et al., 2004). Our metabolic studies also show that in WT+MI mice, there
is a significant negative correlation (r=-0.82) between sodium intake and urinary sodium
excretion, indicating an even higher increase in sodium and water retention as compared to TNF
KO+MI mice. Conversely, we found a significant positive correlation between sodium intake
and urinary sodium (r=0.66) in TNF KO+MI. The 24-h urine volumes were also lower in the
WT+MI mice compared to TNF KO+MI mice.
Most of the effects of the RAS, including fluid balance and endocrine secretion, are
mediated by AT1Rs (Unger et al., 1988). In this study, the increased fluid intake was
accompanied by a decreased urine output, resulting in fluid retention in CHF. These changes
were associated with an increased AT1R and a decreased AT2R expression within the
hypothalamus and brainstem. Moreover, the lung/body weight ratios were higher in WT+MI
mice. These changes were significantly attenuated in TNF KO mice. The elevated superoxide
levels observed in CHF in the PVN and VLM regions of WT, but not TNF KO mice, therefore,
indicate that TNF contributes to unusual drinking behavior, sodium and fluid retention, all of
which can possibly be mediated through AngII mechanisms.
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There is enough evidence to show that high levels of AngII in the CNS of CHF animals
enhance sympatho-excitation through AT-1R activation (Sasaki et al., 1990; Veerasingham et
al., 1997; Li et al., 2006). In the past, Kumagai and Reid (Kumagai et al., 1994) showed that
systemic administration of the AT-1R antagonist losartan inhibited the pressor and renal
sympathoexcitatory responses to carotid occlusion, demonstrating the role of AngII in carotid
occlusion induced sympathoexcitation. Additionally, ICV administration of AngII resulted in
BP, RSNA and NE level increases (Campese et al., 2002). AngII induced increases in BP,
RSNA, and NE are mediated through up-regulation of AT-1R and downregulation of nNOS, the
primary source of NO in CNS neurons (Campese et al., 2005), but the precise mechanism by
which AngII induces sympathoexcitation is still not completely clear. NO is a well known
sympatho-inhibitory neurotransmitter in the CNS and administration of NO inhibitors ICV
resulted in elevated arterial pressure and sympathetic outflow (Sakuma et al., 1992; Zanzinger et
al., 1995). Inhibition of NO prior to ICV infusion of AngII attenuated the increase in BP and
RSNA. In addition, blockade of AT-1Rs concurrent with infusion of a NO donor lowered the
basal RSNA in CHF rabbits, suggesting an important correlation between AngII and NO (Liu et
al., 1999; Zucker et al., 2004). Besides AngII, elevated TNF levels in the PVN can also evoke
sympathoexcitation (Kang et al., 2006; Guggilam et al., 2007). Previous studies underscore the
importance of the interaction between cytokines and the RAS in increased sympathetic activity
in CHF. However, elevated cytokine levels were detected even before neurohumoral activation
in early HF (Torre-Amione et al., 1996), indicating the important role of cytokines in the
progression of CHF. The attenuated NE levels and AT-1R expression in the hypothalamus and
brainstem in the WT mice compared to the ETN-treated mice and TNF KO+MI mice, in our
study, suggest the major intermediary role of TNF in sympathoexcitation.
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The expression of nNOS was significantly decreased in the PVN and RVLM of WT+MI
mice as compared to ETN-treated or TNF KO+MI mice, suggesting that TNF has a significant
role in altering NO-induced sympatho-inhibitory effects. Alternatively, CHF induced an
increased expression of iNOS in the PVN and RVLM with the concurrent increase in O2•−,
resulting in an increased formation of OONO• in these brain regions of WT+MI mice, thereby
negating the NO effect on reducing sympathoexcitation. A previous study by Zanzinger et al.
showed that O2•− and NO interact in the RVLM resulting in formation of OONO•, leading to
damage of these neurons. They also reported that microinjection of OONO• into the RVLM
caused dose-dependent transient excitatory responses (Zanzinger, 2002). However, results from
the present study indicate that in CHF, TNF contributes significantly to the interaction of O2•−
and NO in the PVN and RVLM. It is also possible that the NO produced from eNOS and iNOS,
as well as NO from other regions of the brain, diffuse into the PVN and VLM contributing
towards the formation of OONO•, as indicated by our ESR and immunofluorescence studies. The
reduced nNOS expression, and the increased ROS produced in the PVN and RVLM (Zanzinger,
2002), decrease the bioavailability of NO contributing to sympathoexcitation.
ROS act as key modulators of increased neuronal activity in the PVN and supraoptic
nucleus (SON) of CHF animals (Lindley et al., 2004). The expression of FosB, Fra1, and Fra2
are well recognized to remain elevated under conditions of chronic neuronal stimulation, such as
the CHF (Vahid-Ansari et al., 1998). The present study shows that CHF induces Fos expression
in the PVN and RVLM of WT mice. Interestingly, the increased Fos expression was attenuated
in TNF KO+MI mice, again suggesting the role of TNF in neuronal excitation. These results
were comparable to previous studies where the increased numbers of Fos-positive neurons were
detected in the PVN and SON at both 2 and 4 weeks after MI (Lindley et al., 2004). In addition,
elevated AngII levels in CHF were shown to induce Fos activation in the PVN and SON
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(Lindley et al., 2004). These increased Fos levels were inhibited significantly by a ROS
scavenger, indicating the importance of ROS in sympathoexcitation (Lindley et al., 2004). Also,
the c-Jun/JNK/c-fos pathway is involved in the up-regulation of AT-1R expression by specific
transcription factors (Chan et al., 2002). High levels of AngII and AT-1Rs alter potassium
channel proteins and decreased the overall K+ current (Gelband et al., 1997), resulting in
sympathoexcitation which is the hallmark in the progression of CHF (Zucker, 2006). Taken
together, these results raise the intriguing possibility that TNF induces Fos expression via
modulation of ROS in the PVN and RVLM through an AT-1R mediated mechanism.
In addition, at 4 weeks, ETN-treated mice and TNF KO mice had better-preserved
cardiac function as indicated by improvement in %FS compared to their VEH-treated and WT
counterparts. Pulmonary congestion, as indicated by increased wet lung weight, was reduced in
TNF KO mice compared to WT mice 4 weeks after MI. However, ETN-treatment did not reduce
the pulmonary congestion in CHF. This might be due to the central administration of ETN as
well as the large infarct size. ETN is a soluble fusion protein and cannot cross the blood-brain
barrier. Therefore, most of the effects of ETN are due to inhibition of cytokines in the brain and
are limited to the CNS. Nonetheless, ETN reduced the sympathoexcitation as shown by
decreased NE levels induced by MI.
In conclusion, this study demonstrates that in CHF, TNF induces interaction of O2•− and
NO in the PVN and RVLM, key autonomic regulators of cardiovascular function, through an
AT-1R mediated mechanism, resulting ultimately in sympathoexcitation. This study also
suggests a biologically important cross-talk between the RAS and pro-inflammatory cytokines in
the PVN and RVLM. Functionally, this cross-talk leads to an uncontrolled ROS production that
in turn can act as second messengers for further amplification of TNF and/or AngII activation,
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resulting in increased neuronal firing in the PVN and RVLM and contributing to
sympathoexcitation and disease progression in the failing heart.
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CHAPTER 5
SYSTEMIC TNF TREATMENT INCREASES SYMPATHOEXCITATION THROUGH
OXIDATIVE STRESS AND AT1 RECEPTORS IN THE PARAVENTRICULAR
NUCLEUS
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INTRODUCTION
Congestive heart failure is mainly characterized by an increase in neurohormones and
pro-inflammatory cytokines. Therefore, most of the treatment strategies targeted to improve
heart failure include β-blockers, ACE inhibitors and aldosterone antagonists. Following the
demonstration by Levine et al. that circulating tumor necrosis factor-alpha (TNF) levels are
increased in patients with severe heart failure (Levine et al., 1990), subsequent investigations
have focused on TNF mechanisms in the pathogenesis of CHF. Overexpression of TNF, by
itself, can mimic the phenotype of heart failure and, thus, appears to be a valid therapeutic target
for heart failure therapy. Although anti-TNF treatment strategies were successful in smaller
short-term studies, larger long-term studies (RENAISSANCE, RECOVER, RENEWAL,
ATTACH) were not successful for of various unknown reasons. Nonetheless, most interventions
to improve heart failure were accompanied by a decrease in circulating TNF (i.e., milrinone and
some phosphodiesterase inhibitors) (Molnar-Kimber et al., 1993).
Experimental findings from Mann’s lab revealed that in rats, chronic TNF infusion
results in left ventricular contractile dysfunction and dilatation (Bozkurt et al., 1998). TNF acts
on cardiac myocytes to increase tetrahydrobiopterin synthesis, a co-factor necessary for the
expression of inducible nitric oxide synthase (iNOS) (Nakayama et al., 1994), thus, increasing
nitric oxide (NO) production. This increased NO in the heart can decrease the contractility of
cardiac myocytes (Finkel et al., 1992) leading to cytotoxicity and ultimately apoptosis (Pinsky et
al., 1995). It is well documented that TNF also exerts its toxic effects on heart by altering
antioxidant status, thereby, inducing oxidative stress. NADPH oxidase is a multimeric enzyme
and is responsible for the reduction of oxygen and electron transport, and constitutes a major
source of superoxide production both at cardiac myocytes and vascular smooth muscle level. We
have recently demonstrated that chronic TNF infusion induces myocardial toxicity via
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mitochondrial dysfunction (Mariappan et al., 2007). In our CHF studies, using TNF blockers, we
also showed that TNF is involved in increased NADPH oxidase subunit expression both in the
heart and cardiovascular regulatory centers of the brain (Guggilam et al., 2007). However, CHF
is a complex phenomenon and further studies are required to delineate the central effects induced
by systemic TNF.
Altered fluid homeostasis and increased sympathoexcitation are other important aspects
in patients with CHF. Our previous studies have shown that pro-inflammatory cytokine (PIC)
levels were increased in the hypothalamic paraventricular nucleus (PVN) within 30 min after
myocardial infarction (Francis et al., 2004). Furthermore, we showed that this increase in PICs in
the PVN is simply not an epiphenomenon, but are involved in ROS production in the PVN and
contribute to sympathoexcitation in CHF. Recent studies also show that angiotensin infusion into
the brain can also stimulate ROS production and lead to neuronal excitation. However, in CHF,
several neurohumoral systems are activated that might together contribute to the increased ROS
production in the PVN and in sympathoexcitation. We predict that the increased systemic TNF
can alone stimulate and act on the cardiovascular regulatory center, PVN and contribute to
sympathoexcitation and volume overload. Thus, we conducted the present study by treating rats
systemically with TNF and to study the effects on the autonomic regulatory neurons of the PVN.
This study helps to delineate the relationship between neurohormonal/cytokine activation and
sympathoexcitation that is otherwise observed in a heart failure setting. Along with TNF, we also
used ROS and AT1R blockers systemically to investigate the effector molecules induced by TNF
and the signaling mechanisms.
METHODS
Chronic TNF Infusion Model. Male Sprague-Dawley rats weighing between 275-325 gm were
used. After baseline echocardiography, the rats were randomly allocated to different treatments
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for 5 days: human recombinant TNF (10 μg/kg, IP) + vehicle or pentoxyfylline (PTX, a cytokine
synthesis inhibitor; 30 mg/kg, IP) or Etanercept (ETN, a TNF receptor fusion protein; 1 mg/kg,
SC) or tempol (TEM, a superoxide dismutase mimetic; 200 nmol/kg, PO) or Losartan (LOS, an
AT1R blocker; 0.2 mg/kg, IP). The study conforms to the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised 1996). All the experimental procedures
were approved by the Louisiana State University Animal Care and Use Committee.
Assessment of Cardiac Structure and Function. Cardiac function was assessed by
echocardiography at baseline (day 0) and day 5 of the experiment. Echocardiography was
performed in rats anesthetized with 1.5% isoflurane/oxygen with Toshiba Aplio SSH770 system
(Toshiba Medical Systems, CA) fitted with a PST 65A sector scanner (8 MHz), which generates
two-dimensional images at frame rates ranging from 300 to 500 frames per second. IVSTd and
IVSTs, inter-ventricular septal thickness at end-diastoleand end-systole, respectively; LVIDd and
LVIDs, left ventricular internal diameter at end-diastole and end-systole, respectively; LVPWTd
and LVPWTs, left ventricular posterior wall thickness at end-diastole and end-systole,
respectively were measured using two-dimensional short-axis imaging. LV percent fractional
shortening (%FS) was calculated as: %FS = (LVIDd – LVIDS)/LVIDd x100%.
After the experiment, the hearts were excised, and left ventricles were dissected and snap
frozen in liquid nitrogen and stored at –80°C until further analyzed.
Plasma TNF Levels. At the end of the 5-day study, one group of rats was sacrificed by
decapitation with guillotine under deep anesthesia by isoflurane and approximately 4 mls of
trunk blood was collected in heparinized tubes. Plasma samples obtained by centrifugation of
heparinized blood at 4ºC (Beckman-Coulter) at 2500 rpm for 15 min were used for estimation of
circulating TNF-α and catecholamines. Circulating levels of TNF-α were quantified using
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commercially available rat TNF-α ELISA kit (Biosource, Camarillo, CA) as described
previously (Tei et al., 1995; Francis et al., 2003).
Plasma Catecholamines. Plasma norepinephrine (NE) and epinephrine (EPI) were measured
using high performance liquid chromatography (HPLC). Plasma samples were prepared by
adding activated alumina, Tris buffer, EDTA and internal standard DHBA, along with 0.5 ml of
rat plasma. The samples were centrifuged and supernatant separated and rinsed twice in ultra
pure water and filtered through a Millipore filter (Ultrafree MC UFC30GV00, Millipore Corp).
Samples were filtered and injected into an Eicom HTEC-500 system fitted with an HPLC-ECD.
Extraction of PVN by Laser Capture Microscopy (LCM). LCM was conducted in a
dehumidified room (humidity ≤35%), and was kept to less than 30 min per slide to reduce the
loss in recovery of intact RNA. A 7.5 μm laser spot size was used to capture the PVN, at a power
range of 65–80 mW and pulse duration of 550–750 μs. This combination of parameters allowed
efficient retrieval of the entire PVN area and a consistent lifting efficiency of >80%. The number
of laser ‘shots’ used for each sample was kept constant at 1400. These parameters secured a
sufficient and near constant amount of input RNA for comparative real-time RT-PCR analyses
and protein for western blotting. All experiments were performed no less than five times with
five different animals.
Electron Paramagnetic Spin Resonance (ESR) Studies. Superoxide and peroxynitrite
production in the PVN punches were measured using spin-traps and a BenchTop ESRspectrophotometer e-scan (Noxygen Science Transfer & Diagnostics GmbH, Elzach, Germany).
The intensity of ESR spectra was quantified after subtraction of the ESR signal of probe without
tissue sample.
Real-time RT PCR. RNA was isolated from PVN with TRIzol (Invitrogen, CA), treated with
DNAase, and reverse transcribed using random primers reverse transcriptase. Gene transcripts
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were determined by quantitative real-time polymerase chain reaction using SYBR-Green master
mix (Applied Biosystems, CA) on an Applied Biosystems 7900. Gene expression levels were
calculated using the 2 -∆∆Ct method and normalized to GAPDH gene. The level of change was
expressed as fold of respective control values.
Immunohistochemical and Immuonofluorescence Studies. The brain samples were embedded
in optimum cutting temperature medium, and 5 µm-thick transverse sections were obtained and
mounted on Superfrost slides. A general avidin-biotin-peroxidase complex (ABC) procedure was
used to identify Nox1, Nox4, nNOS and 3-nitrotyrosine (3-NT) (Santa Cruz Biotechnology)
neurons. For immunofluorescence studies, formalin-fixed sections were incubated overnight at
4˚C with the primary anti-rabbit c-Fos (Santa Cruz) or anti-rabbit tyrosine hydroxylase (TH)
(AbCam) followed by Cy-3-labeled secondary immunoglobulin (IgG) (Molecular Probes). The
slides were washed and mounted with ProLong Gold anti-fade reagent (Molecular Probes) for
fluorescent microscopy.
For each animal, positive neurons within the borders of PVN bilaterally were counted
manually in two representative 40-µm transverse sections at about –1.80 mm from bregma, and
an average value was reported. NIH ImageJ software was used to confirm the manual cell counts
in the PVN.
Statistics. All data illustrated are expressed as mean ± SEM. Statistical analyses were performed
using GraphPad Prism version 5.00 for Windows, GraphPad Software, CA, www.graphpad.com.
One-way ANOVA was used to observe the differences among groups followed by Bonferroni’s
correction. In all cases, p<0.05 was considered statistically significant.
RESULTS
TNF Induces Cardiac Dysfunction. At day 0, there were no significant differences in the
cardiac parameters between different treatment groups (data not shown). At the end of 5 days,
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TNF treatment resulted in an increased IVSTd and LVPWTd associated with a decreased %FS
and increased Tei index as compared to control rats (Table 5.1). These changes indicate that
chronic TNF treatment decreased the cardiac pumping performance. However, treatment with
TNF blockers, PTX and ETN, superoxide scavenger, TEM, and AT1R blocker, LOS resulted in
normalizing the changes induced by TNF.
TNF Induced TNF Expression. Systemic TNF treatment induced an increase in TNF
transcripts both in the LV and the PVN (Table 5.2). In addition, the circulating TNF levels were
also significantly increased by systemic TNF treatment (Figure 5.1). However, PTX, TEM and
LOS treatment attenuated this increase induced by TNF. ETN was not able to restore the tissue
levels to normal.

Fig.5.1. Plasma TNF Levels. Data are mean ± SEM. ***p<0.001.

TNF Induces Sympathoexcitation. Figure 5.2 illustrates photomicrograph of c-Fos staining in
the PVN neurons. Systemic TNF treatment induced c-Fos expression in the PVN neurons
suggesting neuronal excitation. Decreased staining of neurons for c-Fos in the PVN neurons in
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rats treated with TEM and LOS suggest that this effect of TNF is mediated through ROS and
AT1R mediated mechanisms.

Table 5.1. Echocardiographic Findings.
Control

TNF

TNF+PTX

TNF+ETN

TNF+TEM

TNF+LOS

20

20

18

18

14

14

1.36 ± 0.02

1.59 ± 0.05*

1.33 ± 0.03

1.41 ± 0.03

1.37 ± 0.05

1.34 ± 0.05

2.26 ± 0.03

2.48 ± 0.12

2.43 ± 0.08

2.25 ± 0.03

2.50 ± 0.06

2.05 ± 0.05

6.57 ± 0.08

7.10 ± 0.21

6.98 ± 0.11

7.28± 0.13

7.31 ± 0.13

7.15 ± 0.14

5.27 ± 0.10

5.69 ± 0.18*

5.03 ± 0.05

4.78 ± 0.15

5.06 ± 0.13

5.16 ± 0.18

1.37 ± 0.11

1.57 ± 0.07

1.39 ± 0.03

1.38 ± 0.32

1.38 ± 0.03

1.34 ± 0.31

2.25 ± 0.13

2.15 ± 0.06

2.24 ± 0.03

2.15 ± 0.11

2.25 ± 0.16

2.11 ± 0.44

%FS

37.2 ± 0.94

31.1 ± 0.97*

34.2 ± 0.67

32.6 ± 0.23

35.7 ± 1.45

34.2 ± 1.22

Tei

0.29 ± 0.03

0.38 ± 0.11*

0.25 ± 0.01

0.32 ± 0.01

0.30 ± 0.02

0.31 ± 0.04

HR

327 ± 7.46

366 ± 10.1*

334 ± 4.06

337 ± 4.68

329 ± 3.78

337 ± 7.09

MAP

107 ± 6.32

109 ± 5.65

103 ± 5.13

108 ± 4.55

103 ± 7.20

105 ± 6.06

n

Left ventricle
IVSTd
(mm)
IVSTs
(mm)
LVIDd
(mm)
LVIDs
(mm)
LVPWT
d (mm)
LVPWTs
(mm)

Data are mean±SEM. IVSTd and IVSTs, inter-ventricular septal thickness at end-systole and
end-diastole, respectively; LVIDd and LVIDs, left ventricular internal diameter at end-diastole
and end-systole, respectively; LVPWTd and LVPWTs, left ventricular posterior wall thickness at
end-diastole and end-systole, respectively; %FS, fractional shortening; HR, heart rate; MAP,
Mean arterial pressure. (*, p<0.05)

Figure 5.3 shows that plasma norepinephrine and epinephrine levels were also increased
significantly in rats treated with TNF compared to those treated simultaneously with TNF
blockers, ROS inhibitor and AT1R blocker implying that TNF induced sympathoexcitation is via
ROS or AT1R or both.
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Fig.5.2. Micrograph showing immunostaining for anti-c-FOS in the PVN (A). The bar graph
shows the quantification of c-FOS positive neurons in the PVN (B). Note the evident increase in
anti-c-FOS in the PVN of TNF treated rats compared to those of control and PTX, ETN, TEM
and LOS treated rats.

Fig.5.3. Assessment of Sympathetic Activity. Norepinephrine and epinephrine levels in the
plasma samples analysed using HPLC-ECD. Data are mean ± SEM. ***p<0.001,
**p<0.01versus control; #p<0.05, ##p<0.01, ###p<0.001 versus TNF group.
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Systemic TNF-treatment caused an increase in the protein (Figure 5.4) and gene
expression of TH and AVP (Figures 5.5A and 5.5B), the rate limiting enzyme in catecholamine
sysnthesis and AVP in the PVN. TNF blocker, ROS inhibitor and AT1R blocker significantly
decreased the TNF-induced TH and AVP expression in the PVN.

Fig.5.4. Photomicrograph showing immunostaining for anti-TH in the PVN (A). The bar graph
shows the quantification of TH positive neurons in the PVN (B). Note the evident increase in
anti-TH expression in the parvocellular neurons of the PVN of TNF treated rats compared to
those of control and PTX, ETN, TEM and LOS treated rats.

TNF Increases Nox Subunit Expression and Superoxide Production. In accordance with our
previous study (Mariappan et al., 2007), and in this study as well, low dose TNF induced the
expression of the major catalytic subunit of NADPH oxidase, Nox2 and its homologues, Nox1
and Nox4 in the LV and also in the PVN (Table 5.2). Figure 5.6A shows the protein expression
of Nox1, Nox and Nox4 in the PVN. The quantification of positively stained neurons is shown in
Figure 5.6B. Systemic TNF treatment resulted in a significant elevation of neurons positively
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stained for Nox1, Nox2 and Nox4 indicating an increased production of superoxide in the PVN
in these rats. We further confirmed our findings by measuring direct superoxide production in
the PVN punches of the rats. In accordance with the Nox subunit expression, superoxide
production was increased in the PVN of TNF-treated rats (Figure 5.6C). Treatment with PTX,
ETN, TEM and LOS reduced Nox subunit expression and superoxide production induced by
TNF.
TNF Reduces nNOS Expression. Previous studies showed that in CHF, nNOS expression is
depleted in the PVN. We have also recently showed that the depleted nNOS levels in CHF are
restored by treatment with systemic TNF blocker, PTX (Guggilam et al., 2008). Interestingly, in
this study, systemic TNF treatment decreased both protein (Figures 5.7A and 5.7B) and mRNA
(Figure 5.7C) expression of nNOS in the PVN. These changes were reversed by treatment with
TNF blockers, PTX and ETN. ROS scavenger, TEM, and AT1R blocker, LOS.

Fig.5.5. Gene Expression of TH and AVP in the PVN. Data are mean ± SEM and are
expressed as fold change versus control group data. ***p<0.001 versus control group.
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Table 5.2. Gene Expression in the PVN.

n

TNF

TNF+PTX

TNF+ETN

TNF+TEM

TNF+LOS

20

18

18

14

14

Left ventricle
TNF

4.78 ± 1.13

2.57 ± 1.08

3.17 ± 1.27

1.18 ± 6.00

2.91 ± 10.0

NOX1

3.60 ± 1.93

2.35 ± 0.73

1.17 ± 0.09

1.14 ± 0.08*

1.53 ± 0.10#

NOX2

2.60 ± 0.17

1.23 ± 0.07

1.17± 0.14*

1.67 ± 0.13*

2.00 ± 0.16*

NOX4

3.37 ± 0.53

1.67 ± 0.16

1.85 ± 0.09

1.91 ± 0.72*

1.99 ± 0.17*

eNOS

3.05 ± 0.17

1.32 ± 0.07

1.17 ± 0.19*

1.12 ± 0.63*

1.80 ± 0.86*

iNOS

2.45 ± 0.23

0.95 ± 0.09

0.85 ± 0.11*

1.06 ± 0.12*

0.73 ± 0.06

AT1R

2.87 ± 0.23

1.25 ± 0.06

1.85 ± 0.07*

1.09 ± 0.12*

1.33 ± 0.16

Paraventricular nucleus
TNF

3.67 ± 0.45

1.12 ± 0.38

2.18 ± 0.59

1.57 ± 0.08

1.12 ± 1.20

NOX1

2.91 ± 2.06

0.87 ± 0.08

1.18 ±0.07

1.35 ± 0.13

1.17 ± 0.11

NOX2

2.98 ± 1.30

2.07 ± 0.43

1.19 ±0.19

1.23 ± 0.02

1.37± 0.14*

NOX4

3.93 ± 0.79

1.57 ± 0.14

1.28 ± 0.09

1.65 ± 0.12

1.84 ± 0.19

eNOS

4.20 ± 0.99

0.98 ± 0.06*

0.77 ± 0.22*

1.67 ± 0.40*

0.46 ± 0.09*

iNOS

2.79 ± 0.63

1.33 ± 0.22*

0.71 ± 0.10*

1.10 ± 0.20*

0.52 ± 0.06*

AT1R

3.21 ± 0.28

1.02 ± 0.24*

0.96 ± 0.14*

1.23 ± 0.24*

0.97 ± 0.32*

Values expressed are means±SEM of fold change (2-∆∆Ct) versus control group. (*p<0.05)

TNF Increases Peroxynitrite Formation. In cardiac myocytes, TNF is shown to increase
superoxide and NO production eventually resulting in the formation of peroxynitrite which is
cytotoxic to the cells. Moreover, increased peroxynitrite formation in certain brain regions has
been shown to induce neuronal cell toxicity ultimately leading to sympathoexcitation. We
therefore, stained the PVN with 3-nitrotyrosine, a footprint for peroxynitrite formation (Figure
5.8A). Figure 5.8B shows the quantification of 3-NT positive neurons. We observed a significant
increase in 3-NT positive neurons in TNF-treated rats while PTX, ETN, TEM and LOS
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decreased the TNF-induced peroxynitrite formation in the PVN. These findings were further
confirmed by ESR measurements of peroxynitrite production in the PVN punches.

Fig.5.6. (A) Photomicrograph showing immunostaining for anti-Nox1and anti-Nox4 in the
PVN. (B) The bar graph shows the quantification of immuno positive neurons in the PVN. Note
the evident increased expression of Nox subunits in the neurons of the PVN of TNF treated rats
compared to the other study groups. (C) The bar graph represents the superoxide production as
measured by ESR spectrometer. Note the increased production of superoxide in the PVN
punches of rats treated with TNF alone.

DISCUSSION
Our results show that systemic injections of TNF in rats resulted in a marked increase in
the neuronal expression of Fos protein in the parvocellular neuronal division of the PVN which
is known to regulate the hypothalamic-pituatary-adrenal (HPA) axis. Concomitantly, an increase
in tyrosine hydroxylase (TH)-immunoreactivity and AVP gene expression was observed in this
region indicating activation of the nor-adrenergic hypothalamic neurons, following
administration of TNF. These results were associated with augmented plasma catecholamine
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levels. Furthermore, the expression of nNOS was decreased while that of eNOS, iNOS, AT1R
and 3-NT was increased in the PVN. TNF treatment resulted in increased LV posterior wall
thickness and Tei index, accompanied by a decrease in %FS. These results support the
hypothesis that systemic TNF stimulates sympathetic nervous system, reduces NO
bioavailability and an AT1R mechanism may be involved in these responses.

Fig.5.7. (A) Photomicrograph showing immunostaining for anti-nNOS in the PVN. (B) The bar
graph shows the quantification of nNOS positive neurons in the PVN. Note the decreased nNOS
stained neurons in the PVN of TNF treated rats compared to the other study groups. (C) The bar
graph represents the nNOS gene expression in the PVN. Note that the gene expression of nNOS
is also decreased in the PVN of rats treated with TNF alone.

Increasing evidence indicates that pro-inflammatory cytokines can engage central
nervous system responses by altering neuroendocrine secretion (Beishuizen et al., 2003).
Circumventricular organs (CVOs), highly vascular regions that lack blood brain barrier, permit
cytokine interaction with brain neurons. In addition, CVOs have blood capillaries with greater
permeability and are potential sites of cytokine entry into the brain. These CVOs send efferent
fibers to both magnocellular and parvocellular regions of the PVN mediating their influences on
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neurohypophysial hormone secretion. A recent study showed that peripheral injection of
lipopolysaccharide (LPS) induced Fos-like immunoreactivity in the CVOs, PVN and SON
regions (Carnio et al., 2006). The induction of c-Fos, an immediate early gene has been widely
used as an indicator of cellular activity in the CNS (Morgan et al., 1991). Present data also
demonstrate that Fos, TH and AVP expression are induced in the pPVN by systemic TNF
treatment. These activated centers in the brain can send signals to the neuroendocrine organs
through release of intermediates that include catecholamines and NO (Carnio et al., 2006).
Systemic TNF treatment was also accompanied by an increase in plasma catecholamines, similar
to the effect of LPS, indicating the activation of hypothalamic neurosecretory neurons that
regulate HPA axis activity.

Fig.5.8. (A) Photomicrograph showing immunostaining for anti-3-NT in the PVN. (B) The bar
graph shows the quantification of 3-NT positive neurons in the PVN. Note the increased number
of 3-NT, a footprint for peroxynitrite formation in tissues, positive neurons in the PVN of TNF
treated rats compared to the other study groups.
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Growing evidence suggests that NO in the brain acts to restrain the stimulation of HPA
axis induced by IL-1β, vasopressin and inflammation, resulting in the suppression of antiinflammatory corticosteroids release from the adrenals (Rivier et al., 1994). Systemic LPS
administration increases iNOS expression not only in the glia cells and astrocytes but also in the
neurons. This increase in iNOS in the PVN was shown to be associated with an increased
expression for corticotrophin releasing factor (CRF) (Wong et al., 1996). It is now well known
that NO has inhibitory effects on the magnocellular secretory neurons of the PVN where
oxytocin as well as vasopressin are synthesized. In vitro studies demonstrated that, application of
NO donor inhibits the magnocellular secretory neurons of the PVN and SON while that of a NO
scavenger enhanced neuronal activity (Kadekaro, 2004). Administration of LPS in rats pretreated with a NOS inhibitor augmented the release of oxytocin and vasopressin (Rivier, 2003).
In the present study, a decrease in nNOS was observed with TNF treatment, while the gene
expression of iNOS and eNOS were increased. These changes were associated with a
tremendous increase in the expression of AVP in the PVN accompanied by an increase in Fosimmunoreactivity. These results suggest that the bioavailability of NO is reduced in these
neurons. The NO produced by iNOS and eNOS could be involved in scavenging the increased
superoxide produced in the PVN and this is further confirmed by 3-NT-immunoreactivity,
footprint for peroxynitrite formation, observed in the PVN neurons. In addition, noradrenaline
can stimulate mRNA expression of AVP in the PVN (Vacher et al., 2002), thus the released
catecholamines in response to TNF injections can further potentiate the AVP expression in the
PVN. Thus TNF might play a pivotal role in the feed forward relationship between
sympathoexcitation and volume overload in stress-induced conditions such as CHF.
However, in CHF, apart from cytokines, elevated AngII also activates the PVN directly
via the receptors in the CVOs (Sawchenko et al., 2000). Moreover, in CHF, there is impairment
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of baroreflexes, and atrial receptor triggered inhibition of sympathoexcitatory and AVP releasing
neurons in the PVN. The increased AngII, acts through AT1Rs and excites PVN neurons that
activate sympathoexcitatory outputs to the kidney (Coote et al., 1998). The effects of AT1R are,
at least in part, mediated through superoxide production (Lindley et al., 2004). We have shown
in our previous study that a cross-talk exists between TNF, ROS and AT1R in the PVN of CHF
rats (Guggilam et al., 2008). Here, we validate our results by demonstrating that systemic TNF
can induce sympathoexcitation via the activation of HPA axis. Inhibition of this activation by
losartan further confirms that the effects of TNF are mediated through AT1R. In this study too,
TNF induced activation of the NADPH oxidase subunits, Nox1and Nox4, and was inhibited by
tempol co-treatment, demonstrating that the actions of AT1 and TNF are mediated via
superoxide production.
Our present results show that systemic TNF can stimulate the activity of sympathetic
neurons of the PVN as illustrated by an increase in heart rate. However, at this particular dose,
the MAP was not altered by TNF. The TNF-stimulated AVP expression in the PVN suggests its
presumptive role in the prompting of ACTH secretion and the modulation of cardiac frequency.
In addition, the increase in IVSTd and LVPWTd associated with a decrease in Tei index indicate
that TNF induced diastolic dysfunction in these rats. Alternatively, TNF blockers, ROS quencher
and AT1R blocker significantly altered these changes induced by TNF. Taken together, our
results suggest a putative involvement of AT1 and ROS in the triggering of immediate early
genes and gene expression of iNOS, AVP and TH, is an adaptive response to TNF injection in
the PVN and in the regulation of sympathoexcitaion in response to stress conditions like CHF.
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CHAPTER 6
CONCLUDING REMARKS
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OVERALL SUMMARY OF FINDINGS
Dysregulation of sympathetic activity following MI can exhaust cardiac performance and
eventually lead to CHF. Pro-inflammatory cytokines (PICs) play a critical role in the
pathogenesis of CHF where increased PICs following MI can gain entry into the brain through
the CVOs, or via activation of prostaglandin receptors and thereby affect the CNS. The increase
in PIC production in the brain, or activation of the HPA by peripheral afferents, may lead to
activation of AngII and ROS, both of which may lead to TNF-dependent ROS signaling in the
CNS and the development of cardiovascular diseases, including CHF. Therefore, elucidating the
precise signaling mechanisms of TNF in the CNS is critical for the development of therapeutic
treatments targeted to central PIC signaling. Through a series of rat and mouse studies, we
explored the role of increased TNF in the CNS following MI.
In chapter 2, we demonstrated that in CHF, in addition to plasma TNF, TNF expression is
also increased locally in tissues, particularly in the heart and the PVN of the hypothalamus in the
brain. These results also demonstrate that this increased TNF is associated with increased
expression of the catalytic subunit of the multimeric enzyme NADPH oxidase, Nox2/gp91phox,
and its homologues, Nox1 and Nox4 in the LV and the PVN. Furthermore, decreased DHE
fluorescence in rats treated with the cytokine blocker, PTX, further confirmed that TNF is
involved in the stimulation of superoxide production in the PVN. Taken together, results from
this study indicate that the elevated expression of TNF in the PVN directly, or through induction
of superoxide production, can increase sympathoexcitation.
In chapter 3, we presented the effects of increased TNF in CHF on the free radical nitric
oxide, known to restrain the excitatory neurons of the PVN. At the same time, excessive NO
production in the brain can exert toxic effects on neurons via the formation of the peroxynitrite
radical. Our results demonstrate that the increased TNF following MI decreased nNOS
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expression. The increased iNOS expression observed suggests that the iNOS-derived NO might
be involved in the formation of peroxynitrite radicals contributing to the symathoexcitation in
CHF. We also showed that the increased AT1R expression in the PVN in CHF is PTX
inhibitable. Results from this study clarify the involvement of TNF in decreasing bioavailability
of NO in the PVN, possibly through an AT1R mediated mechanism.
In chapter 4, we examined the sympathoexcitatory effects of TNF by 1) treating the CHF
mice intracerebroventricularly with Etanercept, a TNF fusion protein that prevents the binding of
TNF to its receptors and 2) also by using a TNF knockout mouse model. We found an increase in
pro-inflammatory cytokine (TNF, IL-1β and IL-6) expression in the PVN and VLM regions of
the brain in CHF mice. Alternatively, the expression of an anti-inflammatory cytokine, IL-10,
was decreased in CHF. We also found that superoxide and peroxynitrite production measured in
these brain regions by ESR, adopting specific spin probes, was increased in CHF.
Immunofluorescence and gene expression studies further indicated that nNOS expression is
decreased while that of peroxynitrite and Fos were increased in the PVN and VLM. All these
changes were accompanied by decreased % fractional shortening in CHF mice. Interestingly, all
these changes were attenuated in TNF KO mice and mice treated ICV with ETN, confirming the
sympathoexcitatory effects of TNF. We also demonstrate in this study that the AngII-induced
salt appetite and fluid accumulation in CHF are, in part, mediated through TNF.
In chapter 5, we challenged our findings from the previous chapters by treating the rats
systemically with TNF to delineate the effects of TNF by excluding the effects of
neurohormones that are activated in CHF, contributing to sympathoexcitation. TNF injections
resulted in an increase in plasma TNF levels and TNF expression in organs, including heart and
autonomic regulatory centers of the brain. In addition, systemic TNF increased c-Fos expression,
an immediate-early gene, indicating the TNF-induced neuronal excitation is via the activation of
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the HPA axis. Inhibition of these effects by losartan, an AT1R blocker indicates that these effects
of TNF are mediated through AngII. Systemic TNF also increased the expression of TH in the
PVN, which is a rate limiting enzyme for the synthesis of NE. Furthermore, TNF increased the
AVP expression, suggesting its role in fluid retention and volume overload. Similar to CHF
studies, systemic TNF was able to increase Nox expression concurrently with superoxide and
peroxynitrite production in the PVN. Inhibition of these TNF-induced changes by tempol and
losartan demonstrate that the actions of TNF are mediated through AngII and ROS.
SIGNIFICANCE OF RESEARCH
Despite so many advances in therapeutic strategies, cardiovascular disease remains the
foremost cause of death in the United States. According to the American Heart Association 2009
statistical update, 1 out of 8 deaths reported are due to CHF (Lloyd-Jones et al., 2009). Recent
clinical trials reported an annual sudden-death risk of 8-12% in 3 months after MI, even with
optimal medical therapy including β-adrenoceptor blockade and angiotensin converting enzyme
inhibitor/angiotensin receptor blocker therapy (Pitt et al., 2003). It is well established that
sympathetic over activity is the major factor contributing to the progression of CHF. Although
all the current therapies modulate sympathetic activity, there still is a need to find a better
treatment strategy, yet owing to the continued increasing mortality rate in CHF patients.
There is abundant evidence that pro-inflammatory cytokines are increased after
myocardial injury and can eventually lead to the pathology of CHF. Previous reports have
demonstrated that brain pro-inflammatory cytokines are increased within minutes after MI
(Francis et al., 2004) and contribute to sympathetic hyperactivity (Zhang et al., 2003). Therefore,
understanding the mechanism by which TNF contributes to sympathoexcitation is important in
the development of new therapies.
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We believe that our studies, utilizing transgenic animals or gain-of-function strategies,
have identified new targets in the brain for the treatment of CHF and demonstrated the beneficial
effects of TNF inhibition on the CHF. Systemic blockade of TNF/superoxide can also lead to
neurohormonal feedback decreasing the hyperactivity of the sympathetic nervous system and the
HPA axis in CHF. In addition, targeting the NADPH oxidase complex and subsequent
superoxide production may be an alternative treatment strategy. From a clinical point of view,
however, it is clear that for chronic diseases such as CHF, restraint of uncontrolled
sympathoexcitation is needed, and this can be accomplished through targeting the production of
TNF in the brain. It is possible that in the past, anti-cytokine agents in the clinical trials might not
have crossed the blood-brain-barrier to target the brain cytokines. Our studies suggest that
inclusion of an anti-cytokine agent that crosses the blood brain barrier in the treatment regimen
of CHF patients may change the clinical outcome. Overall, we believe that our studies yielded an
important proof-of-concept work and opened new doors for future studies that will further the
understanding of TNF-induced oxidative stress in contributing to sympathoexcitation in the
pathogenesis of CHF.
FUTURE DIRECTIONS
Although we believe that our aforementioned studies have made significant
contributions in identifying the novel role of elevated TNF in the autonomic regulatory regions
of the brain, further studies are required to better understand the underlying mechanisms of TNFdependent sympathoexcitation in CHF. Our results showed that blocking ROS by tempol
resulted in decreased neuronal excitation in the PVN suggesting the role of superoxide in
sympathoexcitaion. Future studies are needed to examine the transcription factors involved in
superoxide-induced chronic neuronal excitation. Neuronal cultures incubated with AngII
exhibited a steady increase in the levels of tyrosine hydroxylase (TH) and dopamine β124

hydroxylase, both of which are involved in the biosynthesis of norepinephrine involved in the
regulation of sympathetic activity, mediated via the AT1Rs (Yu et al., 1996). These actions were
inhibited by treatment with extracellular signal-regulated kinase (ERK) and mitogen-activated
protein kinase (MAPK) (Yang et al., 1996). Moreover, in CHF, MAPK plays an important role
in the activation of AT1R in the PVN and SFO (Wei et al., 2008). In Alzheimer’s disease, iNOSinduction by TNF was shown to involve JNK/c-Jun and NF-κB transcription factors (Medeiros et
al., 2007) in the CNS. Furthermore, an oligonucleotide against c-Fos attenuated Ang-II induced
increase in TH (Yu et al., 1996). We therefore hypothesize that in CHF, AT1R might be
increased by TNF via a MAPK pathway, and both TNF and AT1R might be linked in the
dimerization of c-Fos and c-Jun to form the transcription factor AP-1 and further the biosynthesis
of norepinephrine. Moreover, recent reports also illustrated that redox mechanisms are involved
in the AngII-induced activation of AP-1 (Puri et al., 1995; Viedt et al., 2004), further confirming
the critical role of superoxide in the modulation of sympathoexcitation. In addition,
understanding the temporal sequence of events following the activation of TNF in these
autonomic regulatory neurons that lead to increased sympathetic activity may help us define
better interventions aimed at blocking the deleterious effects of TNF.
In summary, we believe that our studies identified potential new targets in the CNS
involved in sympathoexcitation in CHF and laid a foundation for a collection of future studies in
understanding the role of TNF-induced oxidative stress in autonomic neurons.
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